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Abstract 
This dissertation was written as part of the MSc in Bioeconomy Law, Regulation 
and Management at the International Hellenic University.  
The purpose of my research is to conduct an extensive legal analysis of the 
existing legal framework on data protection in medical data and clinical research. The 
recent General Data Protection Regulation (EU) 2016/679,"GDPR", enhances the 
fundamental rights of individuals in the field of data protection. Medical data 
specifically, as they refer to a person’s health are sensitive data that require additional 
protection and careful handling. This is the case in clinical research also. This analysis 
includes European Law, namely the Data Protection Directive, the GDPR, Convention 
108, the European Convention on Human Rights (ECHR) and Guidelines on the 
Protection of Individuals with regard to the Processing of medical data and clinical 
research data. 
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Preface 
The basis for this research originally stemmed from my passion in EU law and 
the protection of human rights. As the world moves further into the digital age, 
generating vast amounts of data and born digital content, there will be a greater need 
to analyse the legal framework in data protection and the challenges that arise. How 
can individuals’ rights be adequately protected in the current legislation? How do the 
EU and CoE data protection framework address the data protection in sensitive data? 
Which fundamental rights issues do the processing of sensitive data may create? 
 
I hope you enjoy your reading. 
 
Vretta Maria 
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Introduction 
The EU's General Data Protection Regulation (EU) 2016/679 aims to extend 
data protection to the era of big data and cloud computing, ensuring that data 
protection is a fundamental right that will be regulated consistently throughout 
Europe. Big data is a term used to refer to the study and applications of data sets that 
are too complex for traditional data-processing application software. Big data include 
capturing data, data storage, data analysis, search, sharing, transfer, visualization, 
querying, updating, information privacy and data source1. Any company that serves 
European customers and collects their data should comply with this Regulation, even if 
it is based in a non-European country. The new GDPR is the biggest change in data 
protection legislation over the last 20 years. The new Regulation present clear rules 
tailored to the digital age to provide strong protection. It imposes a higher standard of 
protection for the processing of medical data. New technologies facilitate the 
digitalization of medical information in the form mostly of Electronic Health Records. 
While, digitalization of Health Records is important for improving and revolutionizing 
healthcare services the use of Electronic Health Records carries enormous risks for 
private and security. Medical data is subject to stricter data-processing regime than 
non-sensitive data. In the field of clinical research, the new EU General Data Protection 
Regulation, while aiming to provide better safeguards for individuals’ personal data 
may also have significant implications for data protection practices of researchers, 
industry, and Biobanks around the world. This dissertation thesis aims to provide an 
overview of the new concepts the new General Data Protection Regulation presents 
and to scrutinize the new framework that the Regulation forms in the field of medical 
data and clinical research, along with the repercussions that might occur.  
 
Brief History of Data Protection in Europe 
  
World War II, which ended in 1945, besides the tremendous social and 
economic impacts, led governments, especially in Europe, to realize the necessity of 
                                                 
1
 Hilbert, M., & López, P. (2011). “The World’s Technological Capacity to Store, Communicate, and 
Compute Information”. Science, 332(6025), 60 –65. 
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implementing laws to protect personal data to prevent similar atrocities. Once Hitler’s 
Nazi regime came to power in 1933, the government began to gather card catalogues 
classifying political and racial enemies of the German. One of the methods used to 
identify citizens of Jewish race or descent was the “National Census”. This Census 
required all citizens to declare both their religious beliefs and race.  
In 1948, the United Nations’ Universal Declaration of Human Rights (“UDHR”) 
was adopted, and Article 12 of the UDHR declared that “[n]o one shall be subjected to 
arbitrary interference with his privacy, family, home or correspondence, nor to attacks 
upon his honour and reputation. Everyone has the right to the protection of the law 
against such interference or attacks.”2  
Following the UDHR, Europe responded in the need of protecting human rights, 
personal data and privacy with the European Convention on Human Rights (ECHR). 
ECHR was drafted in 1950 by the newly formed Council of Europe and was entered into 
force on 3 September 1953.  Specifically, Article 8 provides a right to respect for one's 
"private and family life, his home and his correspondence", subject to certain 
restrictions that are "in accordance with law" and "necessary in a democratic society"3.  
Eight fundamental principles of data protection were established by the Organisation 
for Economic Co-operation and Development (“OECD”) in 1980.  The OECD’s data 
protection principles are outlined in Part II of the OECD Guidelines on the Protection of 
Privacy and Transborder Flows of Personal Data4. These principles, revised in 2013, 
reverberate in ensuing data protection legislation that was adopted in different 
countries around the world5.  Hence, the study of these principles became a useful 
introduction into understanding the European regime.  In 1981, the Council of Europe 
adopts the Data Protection Convention, known as Treaty (Convention) 108, rendering 
the right to privacy a legal imperative.  
                                                 
2
 http://www.un.org/en/documents/udhr/ 
3
 https://www.coe.int/en/web/conventions/full-list/-/conventions/treaty/005 
4
 https://www.oecd.org/sti/ieconomy/2013-oecd-privacy-guidelines.pdf 
5
 Colin J. Bennett, (1992), “REGULATING PRIVACY: DATA PROTECTION AND PUBLIC POLICY IN EUROPE 
AND THE UNITED STATES:, Cornell University Press, Ithaca and London  
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In 1983, the German Constitutional Court summarized the value concept of 
data protection with a fundamental decision6. The “Bundeserfassungsgericht”, in its 
landmark decision on the Volkszählungsgesetz (VolkszählungsG) [Law on the General 
Census]7 explained the notion of data protection as the right of informational self-
determination, which can be defined in practice as the desire of individuals for 
assurances that custodians of their personal data will comply with fair information 
practices8 
In 1995, the European Commission (EC) promulgated a new "Directive" which 
was now binding upon EU member states. The Data Protection Directive 95/46/EC9 
obliged each EU member state to implement privacy laws that are "equivalent" to one 
another. It, furthermore, required that data could only be exported to third party 
countries that could guarantee "an adequate level of protection" for European citizens' 
data through their domestic laws or through international commitments. The Directive 
was implemented in 1998 including Article 29 which presented the composition and 
purpose of the Article 29 Working Party (WP29).  
In 2002 EU adopts Privacy and Electronic Communications Directive 2002/58/EC 
which regulated key subjects such as confidentiality of information, traffic data, spam 
and cookies. Directive 2006/24/EC of the European Parliament and of the Council of 15 
March 2006 on the retention of data generated or processed in connection with the 
provision of publicly available electronic communications services or of public 
communications networks and amending Directive 2002/58/EC" was adopted in order 
to regulate telecommunications data which member states had to store them for a 
minimum of 6 months and at most 24 months. Furthermore, police and security 
agencies had the right to request access to IP address and time of use of every email, 
phone call and text message sent or received. However, this Directive was declared 
invalid by the European Court of Justice because it violated the EU Charter of 
Fundamental Rights on 8 April 2014.  
                                                 
6
 Burkert, H. (2000), “Privacy Data Protection. A German/European Perspective” In C. Engel & K. H. Keller 
(ed.), Governance of Global Networks in the Light of Differing Local Values (pp. 43--70). Nomos 
Verlagsgesellschaft.  
7
Germany/Bundesverfassungsgericht/Judgment of 15 December 1983 (‘Volkszählungsurteil’) 
[Judgement on the Census], BVerfGE 65, 1 
8
 David H. Flaherty, (1991) “On the Utility of Constitutional Rights to Privacy and Data Protection” 41 
Cas. W. Res. L. Rev. 831 Available at: http://scholarlycommons.law.case.edu/caselrev/vol41/iss3/14 
9
 https://eur-lex.europa.eu/legal-content/en/TXT/?uri=CELEX%3A31995L0046 
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  Directive 2009/136 amended Directive 2002/58/EC mainly regarding to cookies, 
where it introduced the requirement of prior consent. On 2013 EU issues the 
Regulation 611/2013 on the measures applicable to the notifications of personal data 
breaches under Directive 2002/58/EC.  
2014 was an important milestone in data protection since the Court of Justice 
decides that data about individuals held by Google must be deleted on request. 
Anyone has the right to ask search engines to remove results from queries that include 
their name. The concept of this ruling became known as the “right to be forgotten”10.  
In 2016, after approximately four years of discussions The General Data 
Protection Regulation (EU) 2016/67911 was adopted superseding the Data Protection 
Directive 95/46/EC.  
 
 
                                                 
10
 Google Spain SL and Google Inc. against Agencia Española de Protección de Datos (AEPD) and Mario 
Costeja González, Case number C-293/12". Court of Justice of the European Union. 8 April 2014.  
http://curia.europa.eu 
11
 Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the 
protection of natural persons with regard to the processing of personal data and on the free movement 
of such data, and repealing Directive 95/46/EC (General Data Protection Regulation),  
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1 Legal Framework 
Legal instruments developed by the Council of Europe and the EU often converge 
in the protection of privacy and personal data but they as well present differences in 
certain aspects. 
1.1 Main Legal Instruments 
 
Relating to the Council of Europe legal instruments is the Article 8 of the 
European Convention on Human Rights which protects the rights to privacy and 
personal data and additionally guarantees the right to respect for private and family 
life, home and correspondence12. Another key binding instrument is the Convention for 
the Protection of Individuals with regard to Automatic Processing of Personal Data, 
known as Convention 108.  
In EU primary law Article 16 of the Treaty on the functioning of the European 
Union (TFEU) contains a general EU competence to legislate on data protection 
issues13. The Charter of Fundamental Rights (EU Charter) in articles 7 and 8 
acknowledges the respect for private life and the right to data protection. The principal 
secondary EU law instrument until May 2018 was the Data Protection Directive, which 
was replaced by the General Data Protection Regulation.   
 
1.2 Council of Europe legal framework 
 
ECHR 
 
The European Convention on Human Rights (ECHR)14 was drafted in 1950 by 
the Council of Europe and entered into force in 1953. All Council of Europe member 
states, which now are 47, are party to the Convention including all the EU Member 
States.  
                                                 
12
 Convention for the Protection of Human Rights and Fundamental Freedoms,(1950) 
https://www.coe.int 
13
 Consolidated version of the Treaty on the Functioning of the European Union,(2008) Official Journal C 
326 , https://eur-lex.europa.eu 
14
European Convention on Human Rights, amended 2010, https://www.echr.coe.int 
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The Convention established the European Court of Human Rights (ECtHR) that 
is why it is considered to be the most effective in terms of individual protection against 
human rights violations in Europe. Judgments finding violations are binding on the 
States concerned and they are obliged to conform to them.  The Convention is 
applicable at a national level and it has been incorporated into the legislation of the 
States parties. All domestic courts must therefore apply the ECHR.  The interpretations 
of the Convention provisions by the ECtHR are very significant because through these 
the protection of human rights and freedom evolves and strengths.  
Article 8 of the ECHR guarantees the right to respect for private life, family life, 
home and correspondence. Its scope is very broad15. Nevertheless, the protection 
awarded by Article 8 ECHR is, however, limited. The rights protected in the 1st 
paragraph may be hindered from the conditions laid down in paragraph 2. European 
Court of Human rights has not yet defined in a precise way the notion “private life”. In 
general, ECtHR in its jurisprudence has given a broad interpretation of article 8 which is 
in accordance with the nature of the Court as a living instrument; consequently it must 
take into consideration the constantly changing social, legal or technological conditions 
in order to be “practical” and “effective”16. In many cases though, ECtHR has given 
some examples of the protection that Article 8 of the ECHR provides, such as the mere 
storage of information about an individual private life17, the surveillance on the 
workplace 18 and the surveillance and interception of phone and mail communication19 
among others.  
However, there are limitations which are set by the 2nd paragraph of Article 8. 
There are, according to Article 8.2 cases where the public authorities can legally 
interfere with the rights set out in Article 8.1 under three conditions:  
 
                                                 
15
 Steven Greer , (1997)“The exceptions to Articles 8 to 11 of the European Convention on Human 
Rights”, Council of Europe, Printed at the Council of Europe 
16
 Tyrer v. the United Kingdom, (Application No. 5856/72), Judgement 1978,  
17
 Leander v. Sweden,26 May 1987 (Application no. 9248/81),  
18
 Copland v. the United Kingdom Application No. 62617/00, (Judgment 2007)  
19
Klass and others v. Germany, (Judgment 1978) (Application No. 5029/71),  
  -7- 
a) The interferences must be in accordance with the law. “The national law must 
be clear, foreseeable, and adequately accessible”20. The law must be adequately clear 
in its provisions to provide any individual a sufficient precision of the conditions and 
circumstances in which the authorities are empowered to resort to any interference 
with an individual’s right to private and family life, home and correspondence. Article 
8.2 introduces the requirement of foreseeability.  Laws with general content do not 
meet with this standard21.  
b) They must pursue one or more legitimate aims. Article 8.2 enumerates, with a 
limited list, the legitimate aims which may justify an infringement upon the rights 
protected in the first paragraph.  
c) The restrictions must be “necessary in a democratic society”. It is apparent, 
therefore, that the rights protected by Article 8.1 are not absolute and the ECtHR 
always examines if in a case the above conditions apply. To determine whether the 
impugned measures are “necessary in a democratic society”, it is important that the 
reasons adduced to justify them are relevant and sufficient and the measures are 
proportionate to the legitimate aims pursued22.  The proportionality of a general 
measure balances the interests of the Member State against the right of the 
applicant.  
The primary purpose of Article 8 may involve the adoption of measures 
designed to secure respect for private life23. The affective enjoyment of the rights 
protected by the ECHR not only obliges the States to abstain from any interference but 
also to actively ensure the protection of these rights24.  
Certainly, States enjoy a certain margin of appreciation when implementing 
their positive obligations under Article 8. The breadth of that margin varies depending 
on whether an individual’s existence or identity is at stake or whether the State is 
required to strike a balance involving opposite private and public interests or 
                                                 
20
 Silver and others v. the United Kingdom, (Judgement 1983) (Application No. 5947/72; 6205/73; 
7052/75; 7061/75; 7107/75; 7113/75; 7136/75),  
21
Amann v. Switzerland , (Application No. 27798/95), (Judgement 1983)  
22
 Z v. FINLAND, (Application no. 22009/93), (Judgement 19997)  
23
 The principle was first set out in Case of Marckx v. Belgium, (Application No.6833/74),(Judgment 
1979)  
24
 In the case of K.U. v. Finland (application No. 2872/02), the Court held unanimously that there had 
been a violation of Article 8 (right to respect for private and family life) of the European Convention on 
Human Rights concerning the Finnish authorities’ failure to protect a child’s right to respect for private 
life following an advertisement of a sexual nature being posted about him on an Internet dating site. 
  -8- 
Convention rights. The margin of appreciation is particularly wider when there is no 
European consensus on issues with sensitive moral or ethical issues. 
 
Convention 108  
 
The Convention laid down basic principles for data protection, also referred to 
as the “common core” principles25. Notwithstanding, CoE regulations and in this case 
Convention 108 are addressed to states in line with the standards of international 
Conventions, implying a weaker binding nature26.  
Convention 108 protects persons against infringements of personal data during 
processing and seeks to regulate the Transborder flows of these data. It applies to all 
data processing by the public or the private sector. In addition, it outlaws the 
processing of “sensitive” data on an individual’s race, politics, sexual life, health, 
religion or criminal record when the suitable safeguards by the law do not exist.  
Moreover, it enshrines the person’s right to know what and how many data are stored 
about him or her and to correct them if it is needed and in addition offers a remedy if 
any of the previous elements are not respected. Transborder flows of personal data to 
States where legislation does not provide enough protection is restricted by the 
Convention. Security or defence may lead to limitations on the rights of the individuals.  
However, Convention 108 does not consider consent of the data subject as a 
legitimate ground for processing.  
Currently, the Convention is undergoing a modernisation process. This process 
started in 2010 with CoE‘s regulators trying to ensure that the Modernized Convention 
will be in compliance and compatible with the new GDPR27. In September 2016, the 
CoE published a Draft Modernised Convention 108 that tries to complete these aims28. 
                                                 
25
 Explanatory Report to the Convention for the Protection of Individuals with regard to Automatic 
Processing of Personal Data, (1981) ETS 108 (Explanatory Report to Convention 108) 
26
 Jörg Plakiewicz, (2011), “Convention 108 as a global privacy standard?” International Data Protection 
Conference Budapest 
27
 EU Agency for Fundamental Rights and Council of Europe, “Handbook on European data protection 
law” (2018 edition) (Luxembourg: Publications Office of the European Union.  
28
 “Consolidated text of the modernisation proposals of Convention 108 finalised by the CAHDATA” 
(meeting of 15-16 June 2016 (Draft Modernised Convention 108) 
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In May 2018, the Committee of Ministers adopted a Protocol amending Convention 
10829. 
1.3 EU legal framework  
 
 Charter of Fundamental Rights of the European Union 
 
The Charter of Fundamental Rights of the European Union was proclaimed by 
EU in 2000. It sets out the full range of political, economic, civil and social rights of 
European citizens, through the synthesis of international obligations and constitutional 
traditions common to all Member States. The Charter became legally binding on EU 
Member States when the Treaty of Lisbon entered into force in December 2009. 
Article 51 of the Charter states that all Member States as well as EU institutions, when 
implementing EU law, must examine and guarantee all the rights of the Charter. 
Specifically, the rights to private and family life and data protection are protected by 
article 7 and 8 of the Convention.  
The Charter must not be confused with the European Convention on Human 
Rights. Although some provisions are relating, the two operate within separate legal 
frameworks: 
 The Charter of Fundamental Rights of the European Union was drafted by the EU 
and is interpreted by the Court of Justice of the European Union (CJEU). 
 The European Convention on Human Rights, on the other hand, was drafted by the 
Council of Europe in Strasbourg and is interpreted by the European Court of Human 
Rights. 
 Unlike the ECHR, the Charter of Fundamental Rights not only guarantees the 
respect for private and family life, but also establishes the right to data protection 
explicitly. Data protection, as a result, became a fundamental right in the EU law.  
On the other hand, there are limitations to the fundamental rights in the 
Charter similar to the ECHR. Article 52.1 of the Charter enumerates the circumstances 
when limitations on the rights and freedoms protected by the Charter are admissible.  
                                                 
29
 Ad hoc Committee on Data Protection (CAHDATA), Protocol (CETS No. 223) amending the Convention 
for the Protection of Individuals with regard to Automatic Processing of Personal Data CM(2018)2- final, 
18 May 2018 
  -10- 
 
Secondary law 
 
Until 2018, under EU law, data protection was regulated primary by Directive 
95/46/EC of the European Parliament and the Council of 24 October 1995 on the 
protection of individuals with regard to the processing of personal data and on the free 
movement of such data (Data Protection Directive, DPD). In 2018, the Directive was 
replaced by the General Data Protection Regulation (GDPR), which was adopted as 
part of the EU Data Protection Reform Package30. 
Furthermore, when balancing other legitimate interests there are more 
detailed data protection provisions that ensure clarity and consistency always 
alongside GDPR. Particularly, Directive 2002/58/EC regulates on the processing of 
personal data and the protections in the electronic communications sector and 
Directive 2000/31/EC sets up a framework on certain legal aspects of electronic 
commerce in the Internal Market and mere conduit.   
In data protection framework Court of Justice of the European Union (CJEU) has 
jurisdiction to determine whether a Member State has fulfilled its obligations under 
Article 7 and 8 Charter of Fundamental Rights and to give preliminary rulings 
concerning the validity and interpretation of the Directive and the Regulation, in order 
to ensure its effectiveness and uniformity.  
 
 Soft law 
 
Soft law refers to non-legally binding instruments such as opinions, 
recommendations, resolutions and declarations, codes of conduct, guidelines and 
communications.  Although they do not have legally binding force they may set 
standards and are important in increasing the value of international agreements or 
other legally binding instruments.  
Soft law constitutes declarations, resolutions of the Council of Europe’s 
statutory organs such as the Parliamentary Assembly and the Committee of the 
Ministers. Also, opinions and studies of the European Commission for the Democracy 
                                                 
30
 Directive (EU) 2016/680, entered into force in 5 May 2018 
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through law (Venice Commission), which is the Council of Europe’s advisory body on 
constitutional matters, are an example of soft law.  In addition, soft law are opinions of 
the European Data Protection Supervisor, which is a supervisory authority devoted to 
protecting personal data and privacy.  
Regarding European Union, in the protection of personal data, an important 
role played the opinions and recommendations of the Article 29 -Working Party31, 
which was an advisory body, composed of representatives from the data protection 
authorities of the Member States of the EU, the European Data Protection Supervisor 
and a representative of the European Commission. As of 25 May 2018 the Article 29 
Working Party ceased to exist and has been replaced by the European Data Protection 
Board (EDPB). It is composed of the head of each Data Protection Authority and of the 
European Data Protection Supervisor (EDPS) or their representatives. The European 
Commission takes part in the meetings of the EDPB without voting rights32. 
 
2 Privacy v. Data Protection 
 
A first distinction between privacy and data protection lies in the scope and the 
limitations of both rights. The distinction is important in order to understand that not 
all situations covered by data protection law are covered by the right to privacy and 
vice versa. These rights are closely related, but they are not the same. In Opinion 
4/2007 on Personal data of Article 29 Working Party there is a reference in the 
difference of the right to privacy and data protection: “the Charter of Fundamental 
Rights of the European Union enshrines the protection of personal data in Article 8 as 
an autonomous right, separate and different from the right to private life referred to in 
Article 7”33. Moreover, the jurisprudence of the European Court of Human rights and 
the Court of Justice of the European Union in many cases separated the function of 
                                                 
31
 The composition and purpose of Article 29 WP was set out in Article 29 of the Data Protection 
Directive.  
32
 Articles 63 to 76 and Recitals 135 to 140 of the GDPR 
33
https://ec.europa.eu/justice/article-29/documentation/opinion 
recommendation/files/2007/wp136_en.pdf 
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these two rights, particularly with reference to the scope of both rights and their 
limitations3435. 
 
Scope and Limitations 
 
“Private life” is a broad concept, which is constantly evolving. Although data 
protection right is also broad the right to privacy covers many other aspects in addition 
to the protection of personal information. Therefore it is much broader than the data 
protection right. The ECtHR has interpreted “private life” as a notion that includes the 
protection of personal data being defined as any information relating to an identified 
or identifiable individual36. A closer analysis, however, of the case law discloses that 
the ECtHR requires an additional element of privacy in order for personal information 
to be included in the scope of private life. This element may be the intrusive nature of 
the processing, because the processing may refer to medical or health data or data of 
vulnerable groups or the processing refers to a permanent or long-term period which 
is a breach of the right to privacy37  
In the substantive scope “private life” does not necessarily include all 
information on identified or identifiable persons. The data protection right, on the 
other hand, does. It protects the processing of personal data relating to an identified 
or identifiable person despite the consequences this processing has on privacy. Even 
outside the privacy context the “data protection right is a fundamental one and it aims 
at facilitating data processing and not forbidding it”38 .  
In the personal scope, in principle, legal persons do not enjoy the right to data 
protection39.The reasoning of CJEU behind this exclusion lies in Article 2(a) and Recital 
2 of the Data Protection Directive(DPD), which limit data protection to natural persons, 
                                                 
34
 CJEU, Joined Cases C-402/05 P and C-415/05 P Kadi and Al Barakaat International Foundation v 
Council and Commission, [2008] ECR I-6351, para. 285. 
35
 CJEU, Case C-28/08 P Commission/Bavarian Lager [2010] ECR I–6055, para. 60 
36
 CJEU, Joined Cases C–92/09 and C–93/09 Volker und Markus Schecke and Eifert [2010] ECR I-11063, 
para. 52. 
37
 ECtHR, Rotaru v Romania App no 28341/95, ECHR 2000-V, para. 44. In this case security services 
detained a file containing information of fifty years about the applicant’s life. The ECtHR decided that 
the processing of information for such a long period of time falls within the scope of “private life”. 
38
 CASE C-101/01, Bodil Lindqvist JUDGMENT OF 6. 11. 2003 — 
39
 CJEU, Joined Cases C–92/09 and C–93/09 Volker und Markus Schecke and Eifert (2010) ECR I-11063, 
para. 58, and Joined Cases C-465/00, C-138/01 
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although the Charter of Fundamental Rights grants to “everyone” privacy and data 
protection. In Recital 14 the new GDPR limits its protection to natural persons and 
does not cover the processing of personal data concerning legal persons, in particular 
undertakings established as legal persons or legal entities. This exclusion contains the 
name of the legal person, the form and the contact details of the legal person. There is 
a “grey zone” in the new GDPR because information that concerns legal persons may 
at the same time be personal data of a natural person, and vice versa In this dilemma, 
it would be instrumental to use the criteria of “purpose”, “content” and “result” in 
evaluating whether or not GDPR should apply,40. Only ECtHR has recognized that legal 
persons have a right to privacy41.  
It must be underlined that even if a case does not concern processing of 
personal data it does not mean that it is not a breach to privacy and for that reason 
must be protected under Article 8 of ECHR. The same applies in cases where there is 
interference with the right to data protection but at the may not constitute a violation 
to private life. It is evident that the rights to privacy and to protection of personal data 
may sometimes overlap and the distinction between them is not always clear in 
practice. 
There is, moreover, a difference between privacy and data protection with 
regard to permissible limitations. The right to privacy is not limited by any means, 
except when interference is justified under certain conditions. 
In the same manner the right to protection of personal data which is protected 
explicitly by the EU Charter in Article 8.2 where the conditions of lawfulness of the 
processing are defined; fairly processing of data for specified purposes and on the 
basis of consent of the person or another legitimate basis provided for by the law. 
Article 52.1 of the Charter will cover the cases where the conditions of article 8.2 for 
the lawful processing of data are not preserved.  
                                                 
40
https://ec.europa.eu/justice/article-29/documentation/opinion 
recommendation/files/2007/wp136_en.pdf pages 23-24.  
41
 Bernh Larsen Holding AS and others v Norway (Application No 24117/08) (Judgement 2013), 
paragraph. 159. 
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3 Overview of Data protection definitions 
 
The data protection terminology is important for the correct application of the 
data protection law especially in sensitive data processing. These concepts were first 
adopted by the Data Protection Directive and are essentially adopted also by the new 
General Data Protection Regulation. Nonetheless, in the new GDPR new elements are 
introduced 
 
3.1  Personal Data 
 
EU law and Council of Europe law define personal data as information relating 
to an identified or identifiable natural person (the data subject), which means 
information about a person whose identity is either manifestly clear or can at least be 
established by obtaining additional information42 The definition of personal data is 
almost the same in Article 4.1 of the GPDR. 
Identified person: Identification involve details which define a person in a way 
that he or she is distinguishable from other persons and recognizable as an individual 
such as an Identification Card Number or data containing name and surname 
combined with the birth date or home address. 
Identifiable person: A person is identifiable when a piece of information 
includes elements of identification through which a person can be identified either 
directly or indirectly. Specifically, it refers to information that although do not 
associate with a name directly, can, with further research, lead to the identification of 
a person. Such details are for example an Internet Protocol (IP) address, location data 
(for example the location data function on a mobile phone)43 or data held by a hospital 
or doctor, which could be a sign that uniquely identifies a person. Whether specific 
information is or not personal data requires de facto analysis of the particular case. 
                                                 
42
 Article 2(a) of the Data Protection Directive and Article 2(a) of the Convention 108. 
43
 Note that in some cases, there is a specific sectoral legislation regulating for instance the use of 
location data or the use of cookies the ePrivacy Directive (Directive 2002/58/EC of the European 
Parliament and of the Council of 12 July 2002 (OJ L 201, 31.7.2002, p. 37) and Regulation (EC) No 
2006/2004) of the European Parliament and of the Council of 27 October 2004 (OJ L 364, 9.12.2004, p. 
1).  
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Recital 2644 of the Data Protection Directive set the benchmark for identifiability. That 
is whether it is possible that reasonable means for identification will be accessible and 
managed by all the foreseeable users of the information. The GDPR has the same 
approach as the DPD but embraces a more precise definition of “identifiable person” in 
Article 4(1).  
The applicability of Data Protection law is not affected by the form in which 
personal data are stored or used. Personal data may be included in written on paper 
and electronically held information, in biometric data (e.g. fingerprints) and even cell 
samples of human tissue which hold and record DNA of an individual person.  
 
 Processing of Personal Data 
 
Processing covers a wide range of operations performed on personal data. 
Forms of personal data processing include collecting, recording, organising, 
structuring, storing, modifying, consulting, using, publishing, combining, alignment or 
combination, restriction, erasure or destruction of personal data. The way of process 
can be either with automated or by manual means. Actions where the data leave the 
responsibility of a Controller and are transferred to the responsibility of another 
Controller are also processing of personal data. Article 4(2) and (6) of the GDPR 
provides for the official definition of “processing”. The term “processing” is presented 
likewise in Article 2 (b) of the DPD and in article 2 (c) of the Convention 108. Under EU 
law “processing” is besides the manual processing of structured filing systems.45. 
In the case of Bodil Lindqvist, for example, The Court has held that “the act 
of referring, on an internet page, to various persons and identifying them by name or 
by other means (giving their telephone number or information about their working 
                                                 
44
 (26) “Whereas the principles of protection must apply to any information concerning an identified or 
identifiable person; whereas, to determine whether a person is identifiable, account should be taken of 
all the means likely reasonably to be used either by the Controller or by any other person to identify the 
said person; whereas the principles of protection shall not apply to data rendered anonymous in such a 
way that the data subject is no longer identifiable; whereas codes of conduct within the meaning of 
Article 27 may be a useful instrument for providing guidance as to the ways in which data may be 
rendered anonymous and retained in a form in which identification of the data subject is no longer 
possible;” Data Protection Directive EU Directive 95/46/EC 
45
 In Convention 108 processing of data files which are not processed automatically also must be 
protected Article 3.2 (c) of the Convention for the Protection of Individuals with regard to Automatic 
Processing of Personal Data 
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conditions and hobbies) constitutes "the processing of personal data wholly or partly by 
automatic means". Moreover, reference to the state of health of an individual amounts 
to processing of data concerning health within the meaning of the 1995 directive”46. 
Other examples of processing can be staff management and payroll 
administration; access to/consultation of a contacts database containing personal 
data; sending promotional emails; shredding documents containing personal data;47 
 
 Data subject 
 
A data subject is any person whose personal data is being collected, held or 
processed. Personal data can refer to anything from a person name, home address or 
ip address. As a result, anyone can become a data subject. As mentioned before48 EU 
data protection law does not, in principle, protect the data of legal persons. Similarly, 
Convention 108 refers primarily to naturals persons. Nonetheless, the domestic 
regulators can extend data protection to legal persons according to article 3.2 (b) of 
the Convention 108.  
 
 Data Controller and Data Processor 
 
In Chapter 1, Article 4 of the GDPR the two notions are defined as below: 
“Controller” is “the natural or legal person, public authority, agency or other 
body which, alone or jointly with others, determines the purposes and means of the 
processing of personal data.” 
“Processor” refers to “a natural or legal person, public authority, agency or 
other body which processes personal data on behalf of the Controller.” 
The respective article in Data Protection Directive about the data Controller 
and the data Processor is Article 2(e) and in Convention 108 Article 2(d). The concepts 
of data Controller and data Processor remain the same under the GDPR as they were 
under DPD. However, GDPR introduces a new concept of “joint Controllers” in Article 
                                                 
46
 Judgment of the Court in Case C-101/01, Bodil Lindqvist  
47
https://ec.europa.eu/info/law/law-topic/data-protection/reform/what constitutes-data-
processing_en 
48
 See chapter 2  
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26 when two or more Controllers together decide the purposes and means of the 
processing of data. Moreover, GDPR regulates differently the Controller-Processor-
data subject relationship.  
 Controllers under GDPR have a high duty to select the Processors with diligence 
by implementing “appropriate technical and organizational measures” and by using 
“only Processors providing sufficient guarantees”49. There must be a binding contract 
between the Processor and the Controller under Article 28.3 which lists also specific 
elements to be included in these contracts, such as duration of the processing, nature 
and purpose of the processing, the type of data and categories of data subjects as well 
as the rights and the obligations of the Controller.  
 Processors under GDPR have certain obligations and might be held responsible 
for not complying with them.  Data subjects whose personal data rights have been 
infringed have the right to an effective judicial remedy against the data Controller or 
against the data Processor and claim compensation from the responsible one. 
 Processors are under an obligation to maintain a record of all categories of 
processing activities. This must include details of the Controllers and any other 
Processors and of any relevant Data Protection Officers (DPOs), the categories of 
processing carried out, details of any transfers to third countries and a general 
description of technical and organisational security measures. These records must be 
provided to the supervisory authority on request. If the Processor has fewer than 250 
employees it is not mandatory except where the processing poses a risk to the rights 
and freedoms of individuals, is not more than occasional and does not include sensitive 
personal data. 
Data Controllers and data Processors have different tasks and responsibilities. 
Data Controller is responsible to decide the process of personal data of other persons 
and data Processor processes these data on behalf of the Controller. In order for the 
data processing to be lawful the data Controller must supervise and inspect the actions 
of the Controller. There is also the case where a Processor can become a Controller if 
he breaches the instructions of the Controller and starts using the data for his or her 
                                                 
49
 Article 28.1 of the GDPR 
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own purposes. Either Controllers or Processors can be public authorities, agencies, 
natural or legal persons.  
 
 Definition of Sensitive Data  
 
Sensitive data are special categories of data which by their nature may impose 
a greater risk to the data subjects and need enhanced protection. In principle, the 
processing of sensitive data is prohibited and is permitted only in exceptional 
circumstances combined with strict safeguards and special conditions.  
Article 6 of the Convention 108 defines sensitive data all personal data that reveal: 
 Racial or ethnic origin  
 Political opinions, religious or other beliefs 
 Health or sexual life 
The Data Protection Directive in Article 8 (1) repeats the categories mentioned in 
Convention 108 but also it adds “trade union membership”. The new GDPR in article 
(1) expands the categories of sensitive data list and include genetic and biometric data, 
which if processed will lead to the unique identification of a person.  
 
 Sensitive vs. non sensitive data 
 
GDPR and DPD present similar rules in that in principle they both prohibit the 
processing of special categories of personal data. The DPD, in Article 8 defines that all 
Member States shall prohibit the processing of sensitive data, with the exemptions laid 
down in paragraph 2, such explicit consent, vital interests etc.  
The GDPR, in Article 9.2, generally replicate the provisions of the DPD in this 
matter. Explicit consent is still a prerequisite for processing personal sensitive data, but 
with additional conditions (see chapter 4 and 6 for analytical presentation of consent). 
Furthermore, in some issues grounds for the processing of sensitive data have been 
extended in GDPR.  
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 Material Scope of Data Protection Law 
 
Under DPD, Article 3, the material scope of data protection is very broad. It 
applies in both automated and manual processing with two exceptions: a) if the 
processing is in the course of purely personal or household activities b) if the 
processing falls outside the scope of European Union Law for example issues 
concerning national security of a Member State.  
GDPR applies to “the processing of personal data wholly or partly by automated 
means and to the processing other than by automated means of personal data which 
form part of a filing system or are intended to form part of a filing system” as stated in 
Article 2.This Regulation does not apply to the processing of personal data: 
(a) In the course of an activity which falls outside the scope of Union Law;  
(b) By the Member States when carrying out activities which fall within the scope 
of Chapter 2 of Title V of the TFEU, for example policies in border control, asylum and 
immigration procedures etc50; 
(c) By a natural person in the course of a purely personal or household activity; 
(d) By competent authorities for the purposes of the prevention, investigation, 
detection or prosecution of criminal offences or the execution of criminal penalties, 
including the safeguarding against and the prevention of threats to public security. 
The activities that fall outside of the scope of the Union Law are mentioned 
both in DPD and GDPR. This exemption is not strict and gives the Member States the 
right to legislate the appropriate measures and laws  
The exception of personal or household activity raised the issue of the difficulty 
to distinguish which processing is purely personal or not. The distinction becomes 
difficult because the rise of social networks gave individuals the power to publish their 
own personal data but unavoidably in many cases publishing the personal data of 
others. Before the new GDPR Article 29 Working party provided some guidelines in 
order to easier distinguish if the processing regards personal or household activities51.  
 
                                                 
50
  https://eur-lex.europa.eu/legalcontent/EN/TXT/HTML/?uri=CELEX:12012M/TXT 
51
Annex 2: Proposals for Amendments regarding exemption for personal or household activities online 
https://ec.europa.eu/justice/article-29/documentation/other-
document/files/2013/20130227_statement_dp_annex2_en.pdf 
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Territorial Scope of Data Protection 
 
The territorial scope of Data Protection is very important in order to delineate 
the extent to which the GPDR is applicable to the processing of personal data in the 
EU/EEA region and outside of it when there is a connection with the EU/EEA territory 
especially in medical data field and clinical research where organisations from EU and 
other non EU countries may be involved. 
The European Economic Area (EEA) consists of 28 Member States, with 
Norway, Iceland and Liechtenstein as members of EFTA52.  
The territorial scope of GPDR is set out in Article 3 and defines broadly the 
term. Businesses that are established in a Member State must comply with the new 
Regulation, exactly as they pertain to DPD. But the new Regulation, unlike DPD, 
introduces wider conditions for applicability of the GDPR. The key differences are the 
following: 
 When Processor or Controller is established in the Union, the GDPR, according 
to article 3, will apply to the processing of personal data in the “context of the 
activities” of a Controller or Processor in the EU, regardless the place of the processing. 
Under DPD the criteria for determining the applicable law was the location of the 
“establishment” of the Controller and the location of the means or equipment used for 
the processing of data. DPD did not refer at all to the location of the Processor in 
Article 4. 
 When the Processor is not established in the EU the GDPR requires compliance 
with the EU Data Protection Law in case the business processes personal data about 
EU data subjects in connection with the “offering of goods or services” (payment is not 
required); or “monitoring” their behaviour within the EU. It must be apparent that the 
organisation “envisages” that activities will be directed to EU data subjects. Moreover, 
GDPR will apply when Member State law is applicable to that place by the virtue of 
public international law. DPD on the other hand although it mentions that national law 
should be applicable to that place by virtue of public international law it only refers to 
                                                 
52
 The European Free Trade Association (EFTA) is the intergovernmental organisation of Iceland, 
Liechtenstein, Norway and Switzerland. EFTA was founded by the Stockholm Convention in 1960. 
Relations with the EEC, later the European Community (EC) and the European Union (EU), have been at 
the core of EFTA activities.  
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cases when the equipment used for processing was situated on Member state territory 
unless it was used only for purpose of transit. 
 Article 27 of the GDPR imposes the obligation to designate, in writing, a 
representative in the EU in the case a company is established outside EU. This 
obligation does not apply to public authorities or bodies, when the processing is 
occasional, does not include processing operations with special categories of data on a 
large scale (Article 9(1)) or concerns personal data relating to criminal convictions and 
offences (Article 10), if these types of processing are unlikely to result in a risk to the 
rights and freedoms of natural persons. Article 4.2 of the Directive, provides for any 
data Controller not established in the EU is required to designate a representative in 
each EU member state in which it meets the 4.1(c) requirements 
 The term “establishment” has been interpreted by the CJEU as a 
““broad” and “flexible” phrase that should not hinge on legal form. An organisation 
may be “established” where it exercises “any real and effective activity – even a 
minimal one” – through “stable arrangements” in the EU. The presence of a single 
representative may be sufficient”53. In the same case the Court has stated that in the 
“context of activities” international business have to demonstrate that there is no 
commercial connection between a local branch or subsidiary and a non EU company 
Controller in order for the DPD not to apply to data processing by a company 
Controller established outside EU54. In the Case C-131/12 Google Spain SL and Google 
Inc. v Agencia Española de Protección de Datos (AEPD) and Mario Costeja González the 
Court gave a broader definition to the term “context of activities”. As stated by the 
Court decision “processing of personal data is carried out in the context of the activities 
of an establishment of the Controller on the territory of a Member State, within the 
meaning of that provision, when the operator of a search engine sets up in a Member 
State a branch or subsidiary which is intended to promote and sell advertising space 
                                                 
53
 Judgment of the Court (Third Chamber) of 1 October 2015, — Weltimmo s.r.o. v Nemzeti Adatvédelmi 
és Információszabadság Hatóság, (Case C-230/14) 
54
 See also: Article 29 Working Party Opinion 8/2010, “Opinion 8/2010 on applicable law” 16 December 
2010   
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offered by that engine and which orientates its activity towards the inhabitants of that 
Member State”55. 
 
4 Key Principles and Rules of the European Data Protection Law 
 
4.1 Structural Safeguards 
 
Convention 108 provides a legal framework with effective safeguards and basic 
principles for data protection. Specifically, personal data shall be “obtained and 
processed fairly and lawfully”, “stored for specified and legitimate purposes”, 
preserved in a form that “permits identification of the data subjects for no longer than 
is required”, the data should be “adequate, relevant and not excessive in relation to the 
purposes for which they are stored” and “accurate and kept up to date”56. 
In Article 6 of the Convention 108 stricter requirements are laid out regarding 
special categories of data: “Personal data revealing racial origin, political opinions or 
religious or other beliefs, as well as personal data concerning health or sexual life, may 
not be processed automatically unless domestic law provides appropriate safeguards. 
The same shall apply to personal data relating to criminal convictions”. 
Additional safeguards of the Convention 108 are “data security appropriate 
security measures”57. Article 8 sets safeguards for the data subject such as access to his 
or her personal data, “rectification or erasure of such data if these have been processed 
contrary to the provisions of domestic law”, remedy if the requests of the data subjects 
are not complied with.  
The Data Protection Directive enshrines the same principles as Convention 108, 
however with more specifications and with the addition of further requirements and 
                                                 
55
 See also: CNIL’s Google Decision Délibération Νο 2013-420 du 3 janvier 2014 de la formation 
restreinte prononçant une sanction pécuniaire à l’encontre de la société X 
56
 Article 5 – Quality of data, Convention for the Protection of Individuals with regard to Automatic 
Processing of Personal Data, (1981) 
57
 Article 7 Data security, Convention for the Protection of Individuals with regard to Automatic 
Processing of Personal Data(1981) 
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conditions58. The GDPR sets the basic principles in Article 5. Restrictions or exemptions 
from the key principles may be provided for at a national level only if three conditions 
are fulfilled: they are provided for by law, pursue a legitimate aim and are necessary in 
a democratic society.  
 
Lawful processing 
 
Article 6 of the Data Protection Directive and article 5 of the new GDPR lay out 
the first principle of lawful processing. ECtHR jurisprudence has interpreted the 
meaning of lawful processing in connection with justified interference under Article 8.2 
ECHR and CJEU jurisprudence defined the conditions for lawful limitations under 
Article 52 of EU Charter59. 
GDPR introduces strict conditions for lawful processing in Articles 6-10 
especially in special categories of data, called sensitive data.  
The processing of Sensitive Personal Data is only permitted under certain conditions60: 
Sensitive Data Processing 
Lawful Basis Data Protection Directive GDPR Analysis 
Explicit consent According to Article 8.2. 
(a) “The data subject has 
given explicit consent”. 
 
According to Article 9.2. 
(a) “The data subject 
has given explicit 
consent”. 
 
Explicit consent 
means that the data 
subject must take 
some positive 
actions to signify 
consent and to be 
free not to consent. 
This can be oral or 
writing.  
Vital Interests of the 
Data Subject 
 “The processing is 
necessary to protect vital 
interests of the data 
subject (or another 
person) where the data 
subject is incapable of 
giving consent” under 
Article 8.2.(c). 
“The processing is 
necessary to protect 
vital interests of the 
data subject (or 
another person) here 
the data subject is 
incapable of giving 
consent» under Article 
9.2. (c). 
This constitutes a 
lawful base if the 
data subject is 
physically or legally 
incapable of giving 
consent.  
Legitimate Interests of 
others 
Article 8.2  
 
Article 9.2  
(b)  
Recitals 47-50 of 
GDPR give the 
                                                 
58
 Article 6, Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the 
protection of individuals with regard to the processing of personal data and on the free movement of 
such data. 
59
 See Chapter 3 for detailed presentation of lawful limitations and justified interference. 
60
 Sensitive Data processing will be examined in detail in the following chapters about Health Data 
Processing and Scientific Research. 
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(b)“The processing is 
necessary in the context 
of employment law”,  
(d) “The processing is 
carried out in the course 
of the legitimate 
activities of a charity or 
not-for-profit body, with 
respect to its own 
members, or persons 
with whom it has regular 
contact in connection 
with its purposes”. 
 (e) “The processing 
relates to personal data 
which have been 
manifestly made public 
by the data subject” and 
“The processing is 
necessary for the 
establishment, exercise 
or defense of legal 
claims”. 
 
“The processing is 
necessary in the context 
of employment law, or 
laws relating to social 
security and social 
protection”. 
 (d) “The processing is 
carried out in the 
course of the legitimate 
activities of a charity or 
not-for-profit body, 
with respect to its own 
members, former 
members, or persons 
with whom it has 
regular contact in 
connection with its 
purposes”. 
 (e) "The processing 
relates to personal data 
which have been 
manifestly made public 
by the data subject”. 
 (f)  
“The processing is 
necessary for the 
establishment, exercise 
or defense of legal 
claims, or for courts 
acting in their judicial 
capacity”. 
definition of what 
may be considered 
“legitimate 
interest». 
Legitimate interests 
of others cannot 
longer be a basis for 
public authorities 
when they process 
personal data in the 
exercise of their 
functions. 
Public Interest   According to Article 
9.2.(g) “The processing 
is necessary for reasons 
of substantial public 
interest, and occurs on 
the basis of a law that 
is, inter alia, 
proportionate to the 
aim pursued and 
protects the rights of 
data subjects”. 
Member States can 
introduce further 
purposes for 
processing sensitive 
data.  
Medical Diagnosis and 
Treatment 
Article 8.3 “The 
processing is required for 
the purpose of medical 
treatment undertaken by 
health professionals”. 
Article 9.2 (h), 9.3 “The 
processing is required 
for the purpose of 
medical treatment 
undertaken by health 
professionals, including 
assessing the working 
capacity of employees 
and the management 
of health or social care 
systems and services”. 
GPDR added in the 
medical diagnosis 
and treatment basis 
the case of 
employee’s health 
and the 
management of 
health or social care 
systems and 
services.  
Historical, statistical or 
scientific purposes 
N/A Article 9.2(j) “The 
processing is necessary 
for archiving purposes 
in the public interest, 
These purposes 
“shall be subject to 
appropriate 
safeguards.” Data 
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for historical, scientific, 
research or statistical 
purposes, subject to 
appropriate 
safeguards”. 
minimization, 
anonymisation and 
data security are 
mentioned as 
possible 
safeguards
61
. 
Exceptions under 
national law 
Member States can for 
reasons of public 
interest, lay down 
additional exemptions. 
Article 9.4 “Member 
States may maintain or 
introduce further 
conditions, including 
limitations with regard 
to genetic data, 
biometric data or 
health data”. 
 GDPR introduces a 
research exemption 
to the general 
prohibition of 
sensitive personal 
data processing. 
Public Health N/A Article 9.2(i) “The 
processing is necessary 
for reasons of public 
interest in the area of 
public health” 
Reasons of public 
interest may be 
protecting against 
serious cross border 
threats to health or 
ensuring high 
standards of 
healthcare and of 
medicinal products 
or medical devices 
 
Purpose specification and limitation 
 
Personal data collected for one purpose should not be used for a new, 
incompatible, purpose. In Data Protection Directive article 6.1 (b) stipulates that 
personal data shall only be collected for specified, explicit and legitimate purposes and 
must not be further processed in a manner that is incompatible with those purposes. 
Further processing of data for historical, statistical or scientific purposes is permitted, 
provided that Member States provide appropriate safeguards62. GDPR repeats that 
personal data must be processed according to the purposes that explicitly enumerates. 
Transfer of data to third parties is a new purpose which needs also an additional legal 
basis.  
 
Data “Minimization”, Accuracy and Storage Limitation 
 
The Controller must implement in all processing operations the data quality 
principles.  
                                                 
61
 Article 29 Working Party Guidelines on consent under Regulation 2016/679, Adopted on 28 November 
2017 As last Revised and Adopted on 10 April 2018,  
62
 Article 89 Safeguards and derogations relating to processing for archiving purposes in the public 
interest, scientific or historical research purposes or statistical purposes 
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 Data minimization: Personal Data in order to be processed must be adequate, 
relevant and limited to the necessary in relation to the purpose for which they are 
collected. In comparison with Article 6.1 (c) of DPD63, GDPR introduces a more 
restrictive obligation to ensure that personal data are «….limited to what is necessary 
in relation to the purposes for which those data are processed." in Article 5.1(c).  
 Accuracy: Controllers have the obligation to ensure that personal data are 
accurate. The accuracy of the data must be examined in the context of the purpose of 
data processing.  
 Storage Limitation: The principle is unchanged, in relation with Convention 108 
and DPD Article 6.1(e) and the data must be erased when the purposes for which they 
were collected are served, but GDPR in Article 5.1(e) defines that if the data were 
collected solely for public interest, or scientific, historical, or statistical purposes they 
can be stored for longer periods.  
 
Fair and Transparent Processing  
 
Fair and Transparency processing means that the controller is obligated to 
explain the process operation to the data subject in an easy and understandable way, 
ensure that the data subject can access his or her data, understand fully the purpose 
their data will be used for and who is the Controller. Unless specifically permitted by 
law the processing of personal data must not be performed in secret. Article 6.1.(a) of 
the Data Protection Directive states that “Personal data must be processed fairly and 
lawfully”. Article 5.1. (a) of the GDPR added “in a transparent manner in relation to the 
data subject” requiring that Controllers take additional care when designing and 
implementing data processing activities. 
 
Accountability 
 
The General Data Protection Regulation (GDPR) integrates accountability as a 
principle which guarantees the enforcement of the Data Protection Principles. Under 
the GDPR, the Controller is obliged to demonstrate that its processing activities are 
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compliant with the Data Protection Principles which was not an obligation under the 
previous Directive 95/46/EC. GDPR’s new accountability obligations require the 
adoption of new technical and organizational measures to demonstrate compliance. 
These obligations include privacy by design, security breach notifications to Data 
Protection Authorities, appointment of a representative Controller or Processor 
established outside the EU and the conduct of Privacy Impact Assessment when the 
processing involves high risk data64.  In Article 31 and 32 GDPR introduces a personal 
data breach notification regime. In the case of personal data breach the Controller 
must without any delay, not later than 72 hours after being aware of it, notify the 
Supervisory Authority competent in accordance with Article 51.  
 
Integrity and Confidentiality  
 
According to Articles 5.1.(f), 24.1, 25.1, 28, 39 and  32 of the GDPR personal 
data must be processed in a manner that ensures appropriate security of those data, 
including protection against unauthorized or unlawful processing and against 
accidental loss, destruction or damage, using appropriate technical or organizational 
measures. 
 
Key Rules on Security of processing and Transparency 
 
According to Article 32 the Controller and the Processor shall implement 
appropriate technical and organizational measures to ensure a level of security 
appropriate to the risk, including inter alia as appropriate: 
Article 12 of the Regulation outlines the rules on Transparency.  The WP29 
guidance also notes that individuals should be able to determine the scope and 
consequences of data processing. Controllers must be clear about how the processing 
will affect the data subject65. 
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5 Data Subject Rights 
 
The new GDPR (Chapter 3, articles 12-23) empowered the rights of the data 
subjects under DPD66 and created new ones.  
 
Right to object 
 
The data subject must be informed on his or hers right to object (Article 21.5) 
and the objection right can be expressed verbally or in writing. The right to object is a 
general right which can be limited only in certain cases such as specific legal 
obligations. Secondly, the right to object includes the data subject’s right to be 
informed, free of charge, and can be raised by the data subject without any 
justification. GDPR provides for that the data subject shall have the right to object at 
any time but in the following circumstances the right to object is not absolute: 
a) Processing is based on legitimate interest according to Article 6.e or on the 
necessity to perform a public interest task (Article 6.f) including profiling. The principle 
of proportionality  must apply in order for the Controller to continue processing 
(Article 21.1) 
b) Processing is made for scientific/historical research/statistical purposes but not 
when the processing is performed for reasons of public interest (Article 21.6).  
The GDPR, unlike DPD which required the data subject to prove that the 
objection was justified67, requires the Controller to demonstrate that he either has 
compelling grounds for continuing the processing, or that the processing is necessary 
in connection with his legal rights. Otherwise, he must cease that processing activity. 
GDPR Article 21.2-3 is similar to Article 14(b) of the Directive but it adds “profiling”. 
“Profiling” refers to a set of data characterizing a category of individuals that is 
intended to be applied to an individual. According to the definition laid out by the 
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Committee of Ministers “Profiling” means an automatic data processing technique that 
consists of applying a “profile” to an individual, particularly in order to take decisions 
concerning her or him or for analyzing or predicting her or his personal preferences, 
behaviours and attitudes68. Moreover, automated processing in Recital 71, 75 and 
Article 22 of the GDPR requires explicitly consent of the data subject and appropriate 
safeguards. Automatic processing is also permitted if: 
 it is necessary for entering into or performing a contract with the data subject 
provided that appropriate safeguards are in place; 
 it is authorised by law;  
According to Recital 59 and Article 12.3-4 of GDPR the Controller must provide 
any requested information in relation to any of the rights of data subjects within a 
month of the request. Under the previous Directive there were no specified time 
limits.  
In case of a breach of their rights data subjects have remedies available in 
national level in different ways:  
 the right to lodge a complaint with supervisory (Article 77) ; 
 the right to an effective judicial remedy where a competent supervisory 
authority fails to deal properly with a complaint (Article 78) ; 
 the right to an effective judicial remedy against a Controller or 
Processor(Article 79);  
 the right to compensation from a Controller or Processor for material or 
immaterial damage resulting from infringement of the Regulation (Article 82). 
Article 83 of the Regulation establishes the general conditions for imposing 
administrative fines. The GDPR sets out significant changes in maximum fines of the 
greater of €20 million or four percent of an undertaking's worldwide turnover69. There 
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are, furthermore, international remedies available. The data subject may bring 
violations before the ECtHR and the CJEU but only to a very limited extent70.  
 
Right to access 
 
Article 8.2 of the Charter of Fundamental Rights and Article 12 of the Data 
Protection Directive contain the aspects of the data subject’s right of access. The 
ECtHR has held that the right to access information about one’s personal data derives 
from the need to respect private life71 .The right to access is the right of any individual 
to obtain information from the Controller about the data that is being processed, the 
purposes for which they are used for and any automated decision process concerning 
him or her. GDPR enriches the mandatory categories of information which must be 
supplied when the data subject requests access in Article 15. In comparison to Data 
Protection Directive, the Regulation adds information about the period for which the 
data will be stored, the existence of rights to erasure, rectification and objection of the 
individual, the right to complain to the Data Protection Authority, where the data were 
not collected from the data subject information as to the source of the data and the 
existence of automated processing that has a significant effect on data subjects.  
Nonetheless, there are some restrictions to the right to access when personal 
data are stored by public authorities. In the case Leander v. Sweden the ECtHR 
concluded that the right to access might be limited in certain circumstances72 
a)overriding legal interests of others b) data processed by scientific purposes and that 
the right to access may not be restricted by undue time limits73.  
 
Right to rectification, erasure and data portability 
 
Right to rectification provides the data subject the power to ask for 
modifications to his or her personal data in case the data subject regards that this 
personal data is not up to date or accurate (Recitals 39, 59, 65, 73 and Article 5.1(d), 16 
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of GDPR). The Directive (Article 6.1d), 12(b)) and the GDPR address this right in the 
same way. 
Right to erasure known as the "right to be forgotten" is the right of a person to 
request for personal data to be erased once the data is no longer necessary. When the 
consent is withdrawn or when certain data are not anymore necessary to fulfill the 
purpose of the processing the legitimate basis ceases to exist.  This is not an absolute 
right, and has to be examined de facto. According to the principle of accountability the 
Controller must demonstrate that there is a legal basis to its data processing otherwise 
the processing must stop.  
Right to data portability means that the data subject can request his or her 
personal data to be transferred in another Controller. It is a new possibility introduced 
by the Regulation in Article 20.  GDPR does not require specific file formats, but WP29 
notes that “a format that can only be read subject to costly licensing constraints would 
be considered inadequate”74. 
 
 
6 Privacy rights and Health Data 
Personal health data including information on drug usage, prescriptions, and 
other medical records and information account to some of the most sensitive data. 
Today new technologies facilitate the digitalization of medical information in the form 
mostly of Electronic Health Records. While, digitalization of Health Records is 
important for improving and revolutionizing healthcare services the use of Electronic 
Health Records carries enormous risks for privacy and security. Many questions arise 
such as who can access the health records of a person; what kind of information these 
records will contain; can anyone use a person’s personal data without informing him or 
her and how important is consent in medical data processing. In clinical research the 
new Regulation will bring the need for operational changes and appropriate controls in 
the research field. Medical data is subject to stricter data-processing regime than non-
sensitive data.  
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The GDPR continues to treat health data as sensitive personal data like the Data 
Protection Directive used to. The GDPR, in particular, adds genetic data and biometric 
data as sensitive personal data and allows Member States to bring in additional 
conditions in the processing of biometric, genetic, and health data. 
6.1 Regulatory framework  
 
Medical Data as Recommendation No.R (97)5 on the Protection of Medical 
Data states in Article 1 are “all personal data concerning the health of an individual. It 
refers also to data which have a clear and close link with health as well as to genetic 
data”75. They refer not only to data held by a doctor about patients but to any person 
likely to keep medical data. Data concerning the state of health of the data subject are 
qualified as sensitive data both under EU and CoE law, specifically in Article 8.1 of the 
Data Protection Directive, Article 9 of GDPR and Article 6 of Convention 108. GDPR 
moreover, introduces genetic and biometric data as sensitive personal data. All data 
contained in medical documentation, in electronic health records and systems should 
be considered to be sensitive data76.  
Medical data in an electronic health record or recorded on paper may be: 
 General numerical information. 
 Diagnostic-related information, laboratory test results, genetic tests, imagery. 
 Treatment information. Prescribed drugs, dosage, effects, and surgeries. 
 Medical correspondence with the doctor. 
 Administrative data, such as hospital social security patient information.  
 Claims data, in case of private insurance claims. 
 Patient/disease registries in hospitals or clinics. 
There are general EU regulations applicable to privacy and data protection and 
sector specific instruments that compound the regulatory framework for medical data 
processing. It is important that any processing concerning medical data must follow 
and comply with the general rules and principles of personal data processing77.  
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The general health data protection framework encompasses Article 8 of the 
ECHR, Articles 7 and 8 of the EU Charter along with Article 6 of Convention 108, the 
Data Protection Directive and the new GDPR. Both the DPD and the GDPR protect and 
distinct certain categories of personal data and state that these categories of data 
require extra protection and can be processed only if special conditions apply and only 
for specific purposes78. The case law of ECtHR, in addition, has in many cases 
established that the collection and storage of medical data or any unauthorized access 
to these data is an infringement of patient’s right to private life according to Article 8 
of ECHR79. Data subjects, as mentioned before, have also the right to bring their case 
before CJEU under certain circumstances that Article 263.4 and Article 267 of the TFEU 
provide for. 
Furthermore, there are health sector specific instruments which consist of 
detailed principles and guidelines for the protection of privacy and data protection. 
They are significant in order to interpret CoE and EU law in the health field: 
 Council of Europe has published Recommendation 97 on Medical Data 
Protection80 and Medical Data Protection Explanatory Memorandum81. Both apply 
principles of Convention 108 to medical data processing in detail.  
 Instruments of European Union are the Article 29 Working Party EHR Report82 
and the European Commission’s eHealth Action Plan 2012-202083. Article 29 Working 
Party EHR Report notably states that “considering the impact of EHR systems and the 
special need for transparency of such systems the safeguards should preferably be laid 
down in a special comprehensive legal framework” and provides detailed presentation 
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of derogations from general prohibition of processing sensitive data. EHR Report84 and 
the European Commission’s eHealth Action Plan 2012-2020 focuses on the patients 
and healthcare employee’s empowerment, on research innovation and future 
technologies in the medical sector. The Action Plan also addresses issues around 
“mobile health” (mHealth) and health & wellbeing applications. After the Action Plan 
the Commission also published the Green Paper85 and the STAFF WORKING 
DOCUMENT on the existing EU legal framework applicable to lifestyle and wellbeing 
apps86 which repeat that the “processing of personal data concerning health is in 
principle prohibited as these data are considered sensitive”. 
 
6.2 Processing Health Data  
 
Under Data Protection Directive in Article 8.1 and the new Regulation in Article 
9.1 processing of personal data concerning health is prohibited. Article 6 of the 
Convention 108 also prohibits processing of sensitive data.  This is a general 
prohibition and both DPD and GDPR set similar grounds for processing medical data, 
although the new Regulation widens the grounds for the processing in the area of 
health management87. Member States may limit or expand the conditions regarding 
health, biometric and genetic data if they consider it appropriate.  
The importance of these data, of course, in order to medically treat patients, 
requires exemptions from the general prohibitions of processing medical data. These 
derogations are laid out in Article 8.2, 8.3 and 8.4 in Data Protection Directive and in 
Article 9.2 and Recitals 51-54 of the Regulation. It is worth noting that all these 
derogations are limited and exhaustive.  
The exemptions are examined separately. 
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Explicit Consent  
 
Data Protection Directive in Article 8.2 stipulates that “Paragraph 1 shall not 
apply where the data subject has given his explicit consent to the processing of those 
data, except where the laws of the Member State provide that the prohibition referred 
to in paragraph 1 may not be lifted by the data subject's giving his consent”. GDPR in 
Article 9.2(a) also requires explicit consent of the data subject with the exception when 
the laws of EU or a Member State define differently.  
In Recital 32, Article 4.11 and 6.1(a) of GDPR, "consent" means any “any freely 
given, specific, informed and unambiguous indication of the data subject's wishes by 
which he or she, by a statement or by a clear affirmative action, signifies agreement to 
the processing of personal data relating to him or her”. "Freely given" the consent 
must be a genuine choice of the data subject and not a result of intimidation, 
misleading, deception, coercion or fear about negatively impacts by withholding 
consent88.  
"Unambiguous" means that the consent must be collected in a manner that 
undoubted indicates the data subject's intentions in providing their agreement to their 
personal data being processed.  
"Statement or clear affirmative action" is the case when a person takes 
deliberate and specific action to opt in or agree to the processing. This includes for 
example signing a consent statement, oral confirmation, a binary choice presented 
with equal prominence, but it does not include silence inactivity, default settings or 
pre-ticked boxes89. The consent must not contain ambiguity but a positive action. Valid 
consent must be both unambiguous and affirmative.  
“Specific” consent is another element of valid consent and is directly related to 
personal data processing purposes. Specific consent is besides strongly linked with the 
element of informed consent. GDPR in Recital 42 states that: “for consent to be 
informed, the data subject should be aware at least of the identity of the Controller and 
the purposes of the processing for which the personal data are intended”. For the 
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consent to be specific it must be in an easily accessible form. The Controller must 
clearly and precisely define the scope, the purposes and the consequences of the data 
processing90.  
“Informed” consent means the consent based upon an understanding and an 
evaluation of the true facts and repercussions of his actions. The right to be informed 
applies no matter whether consent is required or not. The Article 29 Working Party 
guidelines91 on consent have defined the following information that must be 
demonstrated to obtain valid, informed consent, along with article 13 of the 
Regulation: 
 Identity of the Controller. 
 Purpose of each processing operation where consent is the legal ground. 
 Data and type of data that will be collected and used through consent. 
 Information about the right to withdraw consent. 
 Information regarding the use of data for decisions which are solely based on 
automated processing, including profiling. 
 The possible risks of data transfers to third countries  
 The recipients of possible transfers of data. 
The consent must also be “explicit” in the processing of sensitive data. Opt out 
choices do not satisfy the requirement of “explicit” consent. In GDPR, there are two 
types of consent “unambiguous” consent according to Article 4 and “explicit” consent 
according to Article 9.1. Under GDPR Article 9 “explicit” consent is required for the 
processing of certain “special” types of personal data. But is there a difference 
between “unambiguous” consent and “explicit” consent? Not all consent that is 
unambiguous is simultaneously explicit. “Explicit» consent is an “explicit statement” 
regarding the specific personal data to be collected and an explicit action by the 
subject agreeing with this statement. In other words the data subject must opt-in in 
sensitive data. “Unambiguous” consent requires the “clear affirmative action“ for 
example “by filling in an electronic form, by sending an email, by uploading a scanned 
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document carrying the signature of the data subject, or by using an electronic 
signature”92. 
There are many judgments of the ECtHR concerning the matter of lack of 
consent and disclosure of medical data. In L.L. v. France case the Court held that the 
use of the applicant’s, without his consent, by the judge of a confidential medical 
document, namely the correspondence between the applicant’s doctor and a specialist 
was a violation of his private life under Article 8 of the European Convention on 
Human Rights. The medical document had been used by the judge only on a secondary 
basis and the French Court had not justified the interference in view of the 
fundamental importance of protecting personal data93. Another important case is Y.Y. 
v. Russia94. The applicant complained that the St Petersburg Committee for Healthcare 
had collected and examined her medical records and those of her children and 
forwarded its report containing the results of its examination, to the Ministry of 
Healthcare without her consent. The Court found a violation of Article 8 because the 
actions in dispute did not constitute a foreseeable application of the relevant Russian 
law.  
The individual can withdraw consent at any time and must be informed of that 
right prior to giving consent. 
For children below the age of 16, parental consent is necessary for the 
processing of data to be lawful. However, Member States may decide to lower that 
age, but not below 13 according to Article 8 of the GDPR. 
 
To carry data Controller’s obligations in employment law 
 
Article 8.2 (c) of the DPD provided for that in case of sensitive data an 
exception exists when “processing is necessary for the purposes of carrying out the 
obligations and specific rights of the Controller in the field of employment law insofar 
as it is authorized by national law providing for adequate safeguards». Article 9.2 of 
the GDPR allows sensitive data processing when it is necessary for the fulfillment of 
obligation under employment, social security, social protection law or collective 
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agreement. The Regulation has expanded the scope of this derogation as compared to 
the DPD by requiring compliance with collective agreements and obligations under 
social security and social law. Furthermore, Recital 52 of the GDPR clarifies that 
“Derogating from the prohibition on processing special categories of personal data 
should also be allowed when provided for in Union or Member State law and subject to 
suitable safeguards, so as to protect personal data and other fundamental rights, 
where it is in the public interest to do so, in particular processing personal data in the 
field of employment law, social protection law including pensions and for health 
security, monitoring and alert purposes, the prevention or control of communicable 
diseases and other serious threats to health. Such a derogation may be made for health 
purposes, including public health and the management of health-care services, 
especially in order to ensure the quality and cost-effectiveness of the procedures used 
for settling claims for benefits and services in the health insurance system, or for 
archiving purposes in the public interest, scientific or historical research purposes or 
statistical purposes”. 
 
Legitimate activities of non profit 
 
Article 8.2 (d) of the Data Protection Directive provided for that processing is 
allowed when  “is carried out in the course of its legitimate activities with appropriate 
guarantees by a foundation, association or any other non-profit-seeking body with a 
political, philosophical, religious or trade-union aim and on condition that the 
processing relates solely to the members of the body or to persons who have regular 
contact with it in connection with its purposes and that the data are not disclosed to a 
third party without the consent of the data subjects”. The new Regulation does not 
present changes in Article 9.2 (d) about the sensitive medical data processing in regard 
with the nonprofit bodies.  
 
Processing of data related to criminal offences and civil claims 
 
Article 10 of the GDPR provides for that “Processing of personal data relating to 
criminal convictions and offences or related security measures based on Article 6(1) 
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shall be carried out only under the control of official authority or when the processing is 
authorised by Union or Member State law providing for appropriate safeguards for the 
rights and freedoms of data subjects. Any comprehensive register of criminal 
convictions shall be kept only under the control of official authority”. The Regulation 
regards criminal data as sensitive data as the Directive did in Article 8.1.  
 
 
Vital interests of the subject 
 
This is an important derogation in the scope of medical data. Article 9.2(c) of 
the GDPR repeats the wording of the Data Protection Directive in Article 8.2 (c): 
“processing is necessary to protect the vital interests of the data subject or of another 
natural person where the data subject is physically or legally incapable of giving 
consent”. Recital 46 provides further assistance on the matter: “The processing of 
personal data should also be regarded as lawful where it is necessary to protect an 
interest which is essential for the life of the data subject or that of another natural 
person. Processing of personal data based on the vital interest of another natural 
person should in principle take place only where the processing cannot be manifestly 
based on another legal basis…” The vital interests of the data subject are not cited in 
Article 8 of the ECHR. Nonetheless, the vital interests of the data subject are implied in 
the notion of “legitimate basis” of Article 5.2 of Modernized Convention 108 under 
CoE law95. The processing of sensitive personal data can be justified if it is necessary to 
protect the vital interests, life mainly, of the subject or of another person where the 
data subject is physically or legally incapable of providing consent. The processing 
must relate to essential individual interests of the data subject or another person and 
it must be crucial for a life-saving treatment in a situation where the data subject is not 
able to express his intentions and his wills. Nonetheless, if information is available that 
the data subject wouldn’t have given his consent to process, no matter the important 
interests, this provision cannot be a lawful basis. That is why this exception must apply 
only to a small number of medical cases and could not justify processing of personal 
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medical data for purposes other than treatment of the data subject in a life 
threatening situation. Medical care that is planned in advance does not fall in this 
derogation. However, a processing may be based on the grounds of both public 
interest and the vital interests of the data subject or that of another person for 
example where there is a humanitarian emergency. 
 
Data is public  
 
According to Article 8.2 (e) of the DPD the processing is allowed” where 
processing relates to data which are manifestly made public by the data subject or is 
necessary for the establishment, exercise or defense of legal claims”. GDPR has similar 
provisions in Article 9.2 (e) and (f). There is no adequate definition of the concept 
“manifestly made public” under GDPR; however, this exemption is lawful where it is 
unambiguous that the data subject has himself published his personal data in the 
public realm, for example, on his own social media account. In cases such as the 
publishing of personal data in a biography, in the press or on a public personal blog or 
website the intention is apparent96. The publication must result from a free decision of 
the data subject97 On the other hand, there are cases where is difficult to understand 
or interpret the intentions of the data subject. For example, registering for a social 
network might include the acceptance of certain data protection rules which are 
updated and altered constantly. These rules often are long, detailed and dense. Most 
of the data subjects will not read them thoroughly before agreeing. In that way they 
give access to their personal data but without ever “manifestly make them public”. 
Consequently, it is important to carefully use this exception as a lawful base and 
examine each case separately.  
 
Reasons of public interest in the area of public health 
 
The Data Protection Directive (95/46/ EC) allowed, except from the EU or 
Member State law, a data protection authority to lay down exceptions for reasons of 
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substantial public interest98. Article 9.2 (j) of the Regulation, in a narrower exception 
and with the introduction of proportionality, specifies that the reasons of substantial 
public interest must be on the basis of EU or Member State law, “which shall be 
proportionate to the aim pursued, respect the essence of the right to data protection 
and provide for suitable and specific measures to safeguard the fundamental rights and 
interests of individuals”99.  
 
Anonymisation and Pseudonymisation in Health 
 
According to the principle of limited retention of data, that is envisaged in 
Article 5 (e) of the Convention 108 and the Data Protection Directive Article 6. 1. (e), 
personal data must be “kept in a form which permits identification of data subjects for 
no longer than is necessary for the purposes for which the data were collected or for 
which they are further processed.” The time limitation for storing personal data 
applies, however, only to data kept in a form which permits identification of data 
subjects100. In the event that the Controller wants to store these data for a longer 
period of time and since they no longer serve their initial purpose he has to proceed to 
anonymisation.  
Anonymised data are the data which don’t contain any identifying elements. As 
Recital 2 of the GDPR defines, no element must exist in the information, which could, 
by exercising reasonable effect, serve to re-identify the person concerned. The risk of 
re-identification can be assessed by taking into account “the time, effort or resources 
needed in light of the nature of the data, the context of their use, the available re-
identification technologies and related costs”101. Moreover, the anonymised data are 
no longer considered personal and therefore the Regulation does not apply. However, 
this rule has a noteworthy exception: whenever the data subject, for the purpose of 
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exercising his rights gives further information to the Controller facilitating his or her 
identification, those previously anonymised data become personal data again102.  
Pseudonymisation of data is the method of replacing identifying characteristics 
of data with a value, in any form and the data subject cannot be directly identified. 
Pseudonymisation just offers a limited protection for the identity of data subjects in a 
number of cases because identification can be done using indirect means. The 
pseudonymised information still constitutes personal data and therefore remains in 
the scope of the Regulation. According to Article 25.1 of the GDPR there are various 
uses of pseudonymisation as an appropriate technical measure for enhancing data 
protection, and is specifically mentioned for the design and security of its data 
processing103. The Explanatory Report of Modernized Convention 108 in paragraph 18 
provides for that “the use of a pseudonym or of any digital identifier/ digital identity 
does not lead to anonymisation of the data as the data subject can still be identifiable 
or individualised”. Article 25 of the GDPR, which addresses data protection by design, 
explicitly refers to pseudonymisation as an example of an appropriate technical and 
organisational measure that Controllers should implement to accommodate the data 
protection principles and integrate the necessary safeguards. Moreover, 
Pseudonymisation is recommended by the Regulation in the following cases: 
 When processing is incompatible with the purposes for which the personal data 
was initially collected and processed. 
 In the case of organisations that use personal data for historical or scientific 
research or for statistical purposes 
 As an example of a method which best implements “privacy by design and 
default” 
 It fulfills the data security obligations of the Regulation, for example in personal 
data breaches and notification.  
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6.3 Medical Secrecy and health data 
 
Article 8.3 of the Data Protection Directive provided for that “Paragraph 1 shall 
not apply where processing of the data is required for the purposes of preventive 
medicine, medical diagnosis, the provision of care or treatment or the management of 
health-care services, and where those data are processed by a health professional 
subject under national law or rules established by national competent bodies to the 
obligation of professional secrecy or by another person also subject to an equivalent 
obligation of secrecy”. This article introduces the terms “special purposes”, 
“necessary” and “secrecy and confidentiality” for the protection of health data. 
“Special purposes” refers to the processing of sensitive data for the specific purposes 
of therapeutic, diagnostic, after care health services but also the related administrative 
procedures of providing the aforementioned health services. Further processing of 
these data for purposes of medical research for example, is not allowed under the 
DPD. Moreover, the processing must be “necessary” meaning that any processing of 
health data should be soundly justified. The third condition is that the processing of 
sensitive personal data by medical or other staff is subject to professional medical 
secrecy. Article 90.1 of the GDPR introduces a different approach in professional 
secrecy, by stating that it is in a Member State’s discretion to adopt rules about 
secrecy and that the rules adopted by a Member State enacting “an obligation of 
professional secrecy or other equivalent obligations of secrecy” must be in the context 
of necessity and proportionality in order to harmonise the right of data protection and 
the duty of secrecy. According to Article 90.2 of the GDPR Member States were obliged 
to notify the Commission about “the rules adopted pursuant to paragraph 1, by 25 
May 2018 and, without delay, any subsequent amendment affecting them”. Non 
medical staff that also processes sensitive data has the same professional obligation to 
confidentiality and protection. Every professional engaged in processing of sensitive 
data is a Processor under Article 4 of GDPR and should comply with the requirements 
of the Regulation and carry out the processing stringently under the conditions that 
processing is necessary and done with equivalent secrecy. It is advisable under Articles 
32.4, 28.3 and 39.1 of the Regulation that all staff is informed about the duty of 
secrecy and signs a binding confidentiality agreement. Nonetheless, the duty of 
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secrecy is closely linked with privacy. Furthermore, although for some professionals in 
healthcare and clinical research there are no obligations of professional confidentiality 
under national law or other rules, the effective exercise of the subject’s autonomy 
requires all involved professionals to keep all information confidential.  
The GDPR has expanded, as discussed earlier, the cases, under which health data 
could be processed. Article 9.2 (h) allows sensitive data processing when it “is 
necessary for the purposes of preventive or occupational medicine, for the assessment 
of the working capacity of the employee, medical diagnosis, the provision of health or 
social care or treatment or the management of health or social care systems and 
services on the basis of Union or Member State law or pursuant to contract with a 
health professional and subject to the conditions and safeguards referred to in 
paragraph 3”. Furthermore Article 9.2 (i) permits processing “for reasons of public 
interest in the area of public health, such as protecting against serious cross-border 
threats to health or ensuring high standards of quality and safety of health care and of 
medicinal products or medical devices, on the basis of Union or Member State law 
which provides for suitable and specific measures to safeguard the rights and freedoms 
of the data subject, in particular professional secrecy”. These two provisions establish 
legal grounds for regulatory uses of health data in health and pharmaceutical sectors, 
but also allow providers of social care to share health data under certain requirements. 
Recitals 53 and 54 require obligations of confidentiality as additional safeguards as to 
protect the rights and freedoms of natural persons. Recital 54 clarifies that “such 
processing of data concerning health for reasons of public interest should not result in 
personal data being processed for other purposes by third parties such as employers or 
insurance and banking companies”.  
Automated decision taking, including profiling, based on sensitive data is 
prohibited and can only be made under explicit consent or under EU or Member State 
law for reasons of substantial public interest grounds according to Article 4.4 and 
Recitals 71 and 72 of the new Regulation. Substantial public interest includes both 
public health and social security. It must be presented by the Member State under the 
principle of proportionality.  
Electronic health records must be handling with precaution. The recipients of 
information in EHR are numerous: private Hospitals and Clinics, private doctors, 
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physiotherapists, occupational therapists, speech therapists, social workers 
psychologists, pharmacists, nurses, diagnostic imaging services, laboratories, 
administrative staff, and other health care providers. Also in these records other staff 
may have access such as the software company that provided and regularly maintains 
the EHR system .All data in EHR are sensitive and all professionals, who have access to 
these data, must comply with the GDPR.  
In the case of Avilkina and Others v. Russia ECtHR held that the element of 
social need to protect public health was missing and there had been a violation of right 
to respect for private and family life104. The applicants were a religious organization 
and they complaint about the disclosure of their medical files to the Russian 
prosecution authorities after they refused to have blood transfusions during their stay 
in public hospitals.  
 
Employment law and health data 
 
According to both the Data Protection Directive and the GDPR there must be 
lawful grounds for processing information about an employee’s health as these data 
are sensitive. As outlined earlier the processing of medical data must follow the 
requirements set out by Article 9 of the new Regulation. In European Union there are 
various employment laws where occupational medicine as a form of preventive 
medicine in the employment context exists105. Moreover, the nature of the job may 
require medical examination of the employee in order to determine his suitability for 
the particular work or in order to grant certain social benefits. In these cases health 
data must be collected exclusively from the employee concerned except if the 
employee has given explicit and informed consent or when the national law provides 
for it.  
The collection of health data when data subjects must undergo medical 
examinations is regarded also very sensitive. These medical examinations may have 
the form of: 
 drugs and alcohol tests  
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 HIV test  
 Genetic Tests106  
In all the above medical examinations the legal basis for the processing is 
important. Legal bases could include the performance of a contract; comply with legal 
obligations, or the employer’s legitimate interests. For special categories of data, the 
GDPR provides for when it is “necessary for the purposes of carrying out the 
obligations and exercising the specific rights of the Controller or of the data subject in 
the field of employment law”107.  
The lawful grounds often overlap. There are in the Strasburg jurisprudence 
cases that have dealt with employees and the protection of their personal data. In the 
case WRETLUND v. Sweden108 the applicant was an office cleaner at a nuclear plant. 
She complained that her obligation to undergo a drug testing interfered with her right 
to respect for her private life under Article 8.1 of the ECHR. The Court decided that 
since the applicant was informed of the particular drug testing, this test was in 
accordance with the law and declared the application inadmissible. Another important 
case was about the HIV test.  In the case of I.B. v. Greece109 I.B was forced to undergo a 
HIV test in response to pressure from other employees and later he was dismissed 
from his job. ECtHR considered that the applicant was a victim of discrimination on 
account to his health status and there was a violation of Article 8(right to private life) 
and Article 14 (prohibition of discrimination) of the ECHR.  
 
6.4 Health Data and New Technologies 
 
The Article 29 Data Protection Working Party published letters110111 regarding 
the framework of the Commission’s mHealth112 and eHealth113 initiative to clarify the 
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definition of data concerning health in relation to lifestyle and wellbeing apps. “Mobile 
health (hereafter “mHealth”)” covers “medical and public health practice supported by 
mobile devices, such as mobile phones, patient monitoring devices, personal digital 
assistants (PDAs), and other wireless devices”114 
In a paper115  and an annex116 on health data in apps and devices, the Working 
Party supports a broad definition of health data, separating health data in three 
categories as regards the mobile devices: 
1. The data are inherently/clearly medical data, when they are processed via the 
app or the device. 
2. The data are raw sensor data that can be use via the app or in combination 
with other data to draw conclusions about the person’s actual health status or 
health risk. 
3. Conclusions are drawn, based on the data collected via the app or the device 
about an individual’s health status or health risk (irrespective of whether these 
conclusions are accurate, legitimate or otherwise adequate or inadequate). 
 
Information derived from the examination of a body part or bodily substance 
(e.g. blood pressure, heart rate e.t.c) information about disease risks (e.g. alcohol 
consumption) and information about the actual physiological or biomedical state of an 
individual also constitute health data according to Article 29 Working Party.  
Furthermore, a grey area exist, as the Working Party states: “If seemingly 
innocuous raw data are tracked over a period of time, combined with other data, or 
transferred to other parties who have access to additional complementary datasets, it 
may well be that even the seemingly most innocuous data, combined with other data 
sources, and used for other purposes, will come within the definition of ‘health data’.” 
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The Working Party considers explicit consent as the most likely legal ground for 
processing health data. Health data processing via apps and devices requires, in line 
with the principle of transparency, that data Controllers clearly inform users “whether 
the data are protected by any medical secrecy rules or not.” 
The Commission has published, in addition, a Staff Working Document117 which 
examines the EU legal framework that applies in lifestyle and wellbeing apps. In brief, 
the Document states that under the previous Directive 95/46/EC:  
 If the data is transmitted outside the device then it is qualified as health data. 
Explicit consent will be required in any event of wellbeing or lifestyle app or device 
processes of location data or other data collected through sensors of the mobile 
device.  
 Application and device developers must observe the data privacy rules  
 The Directive does not apply when the lifestyle and wellbeing apps do not 
transmit outside the user’s device.  
 
7 Scientific Research in health 
 
 Big data have a key role in clinical research, but simultaneously create new 
challenges for data security and privacy. Machine learning is besides developing into 
one of the primary methods in clinical research, bringing new challenges to privacy and 
data security. Clinical research data are sensitive data although their processing is 
crucial for scientific or research purposes and play a key role in discovering new 
treatments. Clinical researchers must recognize the sensitive data that they process; 
the purposes it is used for, the persons that have access to it and guarantee all 
employees are informed and trained to protect them. Moreover, in Biobanks technical 
details regarding cells and tissue samples, personal information about sample donors, 
and research datasets are generated from the use of human bioresources. Balancing 
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the need to protect the privacy of individual donors or research participants with the 
facilitation of effective research is an ongoing challenge.  
The new EU General Data Protection Regulation, while aiming to provide better 
safeguards for individuals’ personal data may also have significant implications for data 
protection practices of researchers, industry, and Biobanks around the globe. The aim 
is to balance privacy with innovative medical research.  
 
7.1 Rules for clinical research and clinical trial under GDPR 
 
According to Article 4 in paragraph 13 of the new Regulation 2016/679 (GDPR) 
genetic data is “personal data relating to the inherited or acquired genetic 
characteristics of a natural person which give unique information about the physiology 
or the health of that natural person and which result, in particular, from an analysis of 
a biological sample from the natural person in question” and in Recital 34 there is a 
definition “Genetic data should be defined as personal data relating to the inherited or 
acquired genetic characteristics of a natural person which result from the analysis of a 
biological sample from the natural person in question, in particular chromosomal, 
deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) analysis, or from the analysis of 
another element enabling equivalent information to be obtained”. The analysis of the 
biological sample is considered to be data, but not the sample itself. The sample is thus 
not protected under EU Data Protection Law118. The GDPR defines biometric data as 
“personal data resulting from specific technical processing relating to the physical, 
physiological or behavioural characteristics of a natural person, which allow or confirm 
the unique identification of that natural person”. 
Clinical research is a medical research undertaken in humans. Clinical trials, 
which fall under the umbrella of clinical research specifically, are experiments or 
observations conducted and are linked to clinical research119. Biomedical or behavioral 
research studies on human participants are designed to analyze biomedical or 
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behavioral interventions, including new treatments (such as vaccines, drugs, dietary 
supplements, and medical devices), known treatments that need additional revision 
and evaluation and compare new drugs negative and positive effects and efficacy to 
older drugs. An ethics committee approval is obligatory in order for a clinical trial to 
begin120. These committees have the competency for evaluating the risk and benefit 
proportion of the trial. Depending on product type and development stage, 
researchers initially enroll volunteers or patients into small pilot studies, and 
subsequently conduct progressively larger scale comparative studies121. Clinical trials 
can vary in size and cost, and they can involve a single research center or multiple 
centers, in one country or in multiple countries. 
The current regime that applies in clinical trials in the EU is the Directive 
2001/20/EC122. The new Clinical Trial Regulation No 536/2014123 will come into 
application probably in 2019. The timing of its application depends on the 
development of a fully functional EU portal and database by the European Medicines 
Agency together with the EU countries and the Commission124. The Regulation 
harmonises the assessment and supervision processes for clinical trials throughout the 
EU, via an EU portal and database. Until the Clinical Trials Regulation EU No 536/2014 
will become applicable, all clinical trials performed in the European Union are required 
to be conducted in accordance with the Clinical Trials Directive. This Directive will be 
repealed on the day of entry into application of the Clinical Trials Regulation. It will 
however still apply three years from that day to125: 
 Clinical trials applications submitted before the entry into application 
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 Clinical trials applications submitted within one year after the entry into application, 
if the sponsor opted for the old system. 
The new Regulation No 536/2014 will strengthen transparency of trial 
information, efficacy of clinical trials and safety of the subjects. The scope of the 
Regulation No 536/2014 is extensive but as regards to the personal data of the persons 
participating in a clinical trial the Regulation requires informed consent and states that 
by law, all information entered in the clinical trial database is publicly accessible, 
except personally identifiable information, commercially confidential information, and 
confidential communication between and among member states126. The legislation of 
Member States where patients are located may differ, so it is essential to ensure that 
explicit consent is appropriate for the type of data that is collected, mainly regarding 
genetic data if it is mandatory by the protocol. 
Together with the new Regulation No 536/2014, GDPR stipulates in Recital 161 
that “for the purpose of consenting to the participation in scientific research activities 
in clinical trials, the relevant provisions of Regulation (EU) No 536/2014 of the 
European Parliament and of the Council¹ should apply”. 
It is important to identify the key roles of the parties in a clinical study in order 
to determine the party that is responsible for compliance with the EU data protection 
rules, the applicable Member State law and how the data subjects can exercise their 
rights under GDPR. Under the Data Protection Directive, the data Controller (i.e. 
sponsor) is responsible for compliance with the rules. Under the GDPR, the concept of 
joint data Controllers is introduced, and obligations on data Processors are imposed.  
The new Regulation No 536/2014 introduces co-sponsorship and non-
commercial sponsorship in clinical trials in Article 72. Unless decided differently in a 
written binding contract, all Sponsors have the full responsibilities of a Sponsor as 
defined in the Regulation No 536/2014 and GDPR. Co-sponsors can jointly establish 
which Sponsor will serve as a contact point for receiving all questions from subjects, 
investigators, or Member States. The clinical trial Sponsor is responsible for 
determining whether the study must comply with the GDPR. If the trial is subject to 
the GDPR, detailed data privacy information, that the GDPR requires, must be provided 
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to all the participants. In clinical research the Sponsor is a Controller. Other entities 
may act as joint127 Controllers (e.g. an investigator in a clinical trial). Anyone appointed 
by the Sponsor to work with the clinical trial, such as personnel, sales, and sub-
contractors e.t.c is a data Processor. Organisations that process and manage clinical 
trial data should carry out data impact assessments (DIA) because sensitive data 
processing “is likely to result in a high risk to the rights and freedoms of natural 
persons”128. A data impact assessment (DIA) must include identification of the need for 
a DIA, description of the information flow, identification of the data processing and 
related risks, description of solutions to reduce or eliminate these risks, the outcomes 
of the DIA and integration of the data protection solutions into the clinical trial. 
Moreover, the Controller will have to consult the supervisory authority in the cases 
where Member State law obliges Controllers to consult with, and/or take prior 
authorisation from the competent supervisory authority especially when the 
processing is referring to public health according to Article 36.5 of the GDPR.  
The Article 29 Working Party has published a useful guide of what kind of 
processing is likely to result in a high risk of rights and freedoms and gives direction on 
how a DIA is carried out129. According to Article 29 Working party an impact 
assessment “should be continuously carried out on existing processing activities” and 
“should be re-assessed after 3 years, perhaps sooner, depending on the nature of the 
processing and the rate of change in the processing operation and general 
circumstances”130. In addition, according to Article 37 of the Regulation 2016/679 the 
appointment of a Data Protection Officer is mandatory where “the core activities of the 
Controller or the Processor consist of processing operations which, by virtue of their 
nature, their scope and/or their purposes, require regular and systematic monitoring of 
data subjects on a large scale;” or when “the core activities of the Controller or the 
Processor consist of processing on a large scale of special categories of data pursuant 
to Article 9 or personal data relating to criminal convictions and offences referred to in 
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Article 10”. Consequently, a Data Protection Officer should be designated when 
sensitive data are being processed in clinical researches and trials.  
If clinical trials are conducted outside the EU, but submitted for marketing 
authorisation in the EU, they have to follow similar principles to the provisions of the 
Clinical Trials Directive (Annex I, point 8 of the Directive 2001/83/). Article 3.1 of the 
GDPR states: 
1. This Regulation applies to the processing of personal data in the context of those 
activities of an establishment of a controller or a processor in the Union, regardless of 
whether the processing takes place in the Union or not.  
2. This Regulation applies to the processing of personal data of data subjects who are 
in the Union by a controller or processor not established in the Union, where the 
processing activities are related to: 
(a) The offering of goods or services, irrespective of whether a payment of the data 
subject is required, to such data subjects in the Union; or 
(b) The monitoring of their behavior as far as their behavior takes place within the 
Union. 
For example, if a medical researcher processes personal data in US and uses a 
data storage service established in the EU, then the US medical researcher is a 
Controller and the data storage service is a Processor. The US medical researcher as a 
Controller must adhere to EU law in regards to the data stored with the European 
service provider. 
GDPR clearly states in Articles 17 and 20 that data subjects have the right to 
erase or transfer their data. In a clinical research this may be challenging. Clinical data 
if removed or transferred from a dataset, may result in altering the audit trail or the 
statistical outcome. How the science community will respond to such challenges is a 
matter yet not resolved. Subjects can, nevertheless, withdraw their consent to prevent 
any additional data collection or exercise their other rights under GDPR. 
Furthermore, Article 12 of the Medical Data Recommendation131 132regulates 
scientific research. The provision requires that medical data used in scientific research 
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shall be anonymised. In addition, it advices professionals and scientific organisations to 
implement techniques and procedures to ensure anonymity. It is, however, possible to 
use personal data if the research pursues a legitimate aim and is impossible to 
continue the research without this data. These conditions should apply: 
1. The data subject or the legal representative of an incapacitated data subject 
has provided informed consent. 
2. The research serves high public interests and it is authorised by the responsible 
national agency. 
                                                                                                                                               
Scientific research 
 
12.1.    Whenever possible, medical data used for scientific research purposes should be anonymous. 
Professional and scientific organisations as well as public authorities should promote the development of 
techniques and procedures securing anonymity. 
 
12.2.    However, if such anonymisation would make a scientific research project impossible, and the 
project is to be carried out for legitimate purposes, it could be carried out with personal data on 
condition that: 
 
a.    the data subject has given his/her informed consent for one or more research purposes; or 
 
b.    when the data subject is a legally incapacitated person incapable of free decision, and domestic law 
does not permit the data subject to act on his/her own behalf, his/her legal representative or an 
authority, or any person or body provided for by law, has given his/her consent in the framework of a 
research project related to the medical condition or illness of the data subject; or 
 
c.    disclosure of data for the purpose of a defined scientific research project concerning an important 
public interest has been authorised by the body or bodies designated by domestic law, but only if: 
 
    i.   the data subject has not expressly opposed disclosure; and 
 
    ii. despite reasonable efforts, it would be impracticable to contact the data subject to seek his consent; 
and 
 
    iii. The interests of the research project justify the authorisation; or 
 
d.    the scientific research is provided for by law and constitutes a necessary measure for public health 
reasons. 
 
12.3. Subject to complementary provisions determined by domestic law, health-care professionals 
entitled to carry out their own medical research should be able to use the medical data which they hold 
as long as the data subject has been informed of this possibility and has not objected. 
 
12.4. As regards any scientific research based on personal data, the incidental problems, including those 
of an ethical and scientific nature, raised by respect of the provisions of the Convention for the Protection 
of Individuals with regard to Automatic Processing of Personal Data should also be examined in the light 
of other relevant instruments. 
 
12.5. Personal data used for scientific research may not be published in a form which enables the data 
subjects to be identified, unless they have given their consent for the publication and publication is 
permitted by domestic law. 
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3. The scientific research is provided for by law and constitutes a necessary 
measure for public reasons.  
 
Article 29 Working Party has expressed similar opinion about the matter133. In 
the Opinion the Working Party is concerned about the status of pseudonymous data in 
the context of research. Specifically, it states in the Opinion that: “Retraceably 
pseudonymised data may be considered as information on individuals which are 
indirectly identifiable. Indeed, using a pseudonym means that it is possible to backtrack 
to the individual, so that the individual’s identity can be discovered, but then only under 
predefined circumstances. In that case, although data protection rules apply, the risks 
at stake for the individuals with regard to the processing of such indirectly identifiable 
information will most often be low, so that the application of these rules will justifiably 
be more flexible than if information on directly identifiable individuals were processed”, 
“identified or identifiable” – focuses on the conditions under which an individual should 
be considered as “identifiable”, and especially on “the means likely reasonably to be 
used” by the controller or by any other person to identify that person. The particular 
context and circumstances of a specific case play an important role in this analysis. The 
opinion also deals with “pseudonymised data” and the use of “key-coded data” in 
statistical or pharmaceutical research. 
Under the GDPR, as mentioned before, pseudonymised data are personal data 
and have to be protected accordingly. Confidentiality and data security provisions 
must be applied to sensitive data processing in the context of clinical trials. Besides 
pseudonymisation, other safeguards (such as encryption) will need to be considered 
and implemented as well according to recital 28. For clinical research projects not 
based on informed consent, like observational studies, the Controller must apply the 
suitable safeguards according to Article 89 of the Regulation. While the GDPR was in its 
development, the Medical Science Committee134 and other commentators were 
concerned about possible negative implications pseudonymised data will have for 
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research135. According to its Opinion, the MED Committee suggested adoption of a 
risk-managed approach in the case of pseudonymised data since there are appropriate 
technical safeguards in the research field that reduce the risk of re-identification 
otherwise, “many research projects will become unmanageable and the ability to 
respond rapidly to medical questions of importance will be limited”. 
Article 9 of GDPR, prohibits processing unless certain conditions are met. In 
Article 9.2.(j) is defined that if the “processing is necessary for archiving purposes in 
the public interest, scientific or historical research purposes or statistical purposes in 
accordance with Article 89(1) based on Union or Member State law which shall be 
proportionate to the aim pursued, respect the essence of the right to data protection 
and provide for suitable and specific measures to safeguard the fundamental rights and 
the interests of the data subject” then the processing is allowed. Article 89, states that 
“Where personal data are processed for scientific or historical research purposes or 
statistical purposes, Union or Member State law may provide for derogations from the 
rights referred to in Articles 15, 16, 18 and 21 subject to the conditions and safeguards 
referred to in paragraph 1 of this Article in so far as such rights are likely to render 
impossible or seriously impair the achievement of the specific purposes, and such 
derogations are necessary for the fulfillment of those purposes.” Scientific research 
according to Recital 159 of the GDPR should be interpreted broadly and it provides 
some examples of what may constitute scientific research. The recital makes a 
reference to Article 179.1 of the Treaty on the Functioning of the European Union, 
which endorses “the objective of strengthening its scientific and technological bases by 
achieving a European research area in which researchers, scientific knowledge and 
technology circulate freely.”It is yet ambiguous if the Regulation requires the research 
to be published, as the Treaty states in order to fall in the scientific research concept. . 
Even so, GDPR prioritizes research in order to foster innovation combined with 
adequate security measures to protect personal data. The Directive permitted 
secondary processing for research purposes provided that the Member States had 
“furnished suitable safeguards”136. Accordingly, the Controller was not allowed to 
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further process personal data outside the purposes for which it was collected, except 
when the member state had endorsed legislation permitting processing activities for 
research purposes. The GDPR makes an exception to the principle of purpose 
limitation for research. Article 5.1 defines that, “further processing for archiving 
purposes in the public interest, scientific or historical research purposes or statistical 
purposes shall, in accordance with Article 89(1), not be considered to be incompatible 
with the initial purposes.”  
Article 6.4 of the GDPR entails that further process of sensitive data for a 
purpose that involves research is permissible even though research was not the 
purpose for the initial collection. Recital 50 of the GDPR states that further processing 
is permissible when the secondary processing is “compatible,” such as for research 
Compatibility is examined according to Article 6.4 in relation to “the nature of the 
personal data, in particular whether special categories of personal data are processed, 
pursuant to Article 9”. On the other hand, under the previous Directive, “further 
processing of personal data concerning health, data about children, other vulnerable 
individuals, or other highly sensitive information should, in principle, be permitted only 
with the consent of the data subject”.137 
Article 8 of the GDPR includes specific provisions for the processing of 
children’s data so Sponsors are required to make “reasonable effort” to ensure that 
the parent or guardian has provided valid consent if the clinical trial includes children.  
7.2 Biomedical research and Biobanks 
 
The enactment of GDPR will affect directly biomedical research in many ways. 
More specifically Biobanks and research organisations must comply with the 
Regulation in order to lawfully continue their research progress and simultaneously 
protect the data subjects’ personal and sensitive information. 
Cell based research especially iPSC research requires all involved parties to 
comply with the GDPR. Induced pluripotent stem cells (iPSC) are a type of pluripotent 
stem cell that can be generated directly from adult cells. iPSC can be derived directly 
from adult tissues and can be made in a patient-matched manner, which means that 
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each individual could have their own pluripotent stem cell line. iPSCs are used in 
personalized drug discovery efforts and understanding the patient-specific basis of 
disease138. The technology of iPSC is currently widely used and has very prominent 
results. When the iPSC is derived from fetal tissue or from a diseased donor then the 
Regulation about the protection of personal data is not applied. Nonetheless, if the 
method is applied in living donors these individual’s sensitive personal data require 
legal protection. The GDPR concerns iPSC that are derived from new donated material 
or existing tissue samples that are not fully anonymous, but pseudonymised139. The 
use of human biological material for cell-based research and clinical interventions has 
many risks to the privacy of patients and donors since these stem cell lines hold 
extensive genetic characteristics of the parent/donor somatic cell or tissue. This poses 
high risks in privacy protection is the possibility of re-identification of individuals from 
anonymised cell lines and associated genetic data140. 
In order to minimize the risk to privacy of the donors/patients, valid consent 
should contain all the necessary information required by the Regulation and certainly 
the purposes the biological sample is collected, can be reprogrammed, can be stored 
and can be shared together with the personal and/or medical data of the participant. 
In order to later derive human iPSC from tissue samples that were obtained previously 
in support of a research plan that did not include iPSC derivation, a new consent for 
the data processing new purpose must be obtained according to GDPR and the 
purpose limitation principle, if it is not compatible with the research purpose. It is 
worth noting that Article 6.4 of the GDPR allows for subsequent processing operations 
that are “compatible.” Moreover, in Recital 50 it defines that further processing for 
research purposes “should be considered to be compatible.” The previous Data 
Protection Directive defined in Recital 29 that secondary processing for research 
purposes was permissible only if the Member States had the necessary “suitable 
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safeguards” .Hence, the Controller could not process personal data further than the 
purposes for which it was collected, except when the Member State had enacted 
legislation allowing these kind of processing activities for research purposes. 
It is obligatory under GDPR to ensure that data subjects understand and 
consent to all the information about how the data will be used and distributed141, so 
health professionals should ensure that participants give permission to share cell lines 
and data with researchers in other countries, the private sector and consent to post-
study deposition of the lines and data in a biobank such as EBiSC142. iPSC researchers 
who generate cell lines and collect clinical data must find and apply, in order to ensure 
a long-term research plan, stable means of access to the pseudonymisation key that 
links individual donors and their samples/data143. For Biobanks and research groups 
who produce and share human iPSC, part of the competences of the designated Data 
Protection Officer could be the responsibility for the protection of the 
pseudonymisation keys, and the competency, as a contact point, to examine 
traceability and re-contact requests144.  
A biobank is a type of biological materials repository that collects, processes, 
stores, and distributes biospecimens, usually human’s to support future scientific 
investigation and for use in research. Biobanks give researchers access to data 
representing a large number of people. Samples in Biobanks and the data derived from 
those samples can often be used by multiple researchers for cross purpose research 
studies145. 
The core activities of Biobanks are processing operations that entail regular and 
systematic monitoring of the data subjects on a large scale, consequently a Data 
Protection Officer must be appointed by the Biobank Controller or the Processor in 
order to assist, monitor and guarantee internal compliance with GDPR. A Data Privacy 
Impact Assessment is also required for the processing of sensitive data by a Biobank.  
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Participants should also be informed, in the informed consent framework, about what 
data will be shared. Research involving genetic data and next-generation sequencing 
data may lead to concerns about (i) whether data can identify individuals and/or family 
members, and (ii) whether to return results from this type of analysis146. 
 
7.3 Secondary use of health data 
 
Secondary use of health data provides personal health information for research 
applications usually after the direct health care. A substantial amount of information is 
collected throughout the provision of care and treatment, some of it specific to the 
patient being treated, some of it not. The use of electronic medical records made the 
mass collection of public health data possible. Secondary use must be performed 
under professional and legal obligations of confidentiality. Practically, secondary use of 
data is applied in order to:  
 Advance the quality of clinical care  
 Protect public health  by monitoring  and responding  to infectious diseases and 
other environmental hazards 
 Improve the management of the health system,  
 Ensure that health policy is evidence-based through carrying out empirical 
research 
 Provide better information to the public about healthy lifestyles  
  Process large amounts of data from multiple sources  
 Research by others using data collected by the care team without being a part 
of it 
 Research which requires further contact with patients or former patients147. 
  
The benefits from the secondary use of information are important. The health 
of the population may be improved by actions such as disease surveillance, screening 
and needs assessment and preventive activities. It is also significant for clinical and 
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medicine safety when evaluating long term effects of drugs and treatments. On the 
other hand, unauthorized disclosure of personal health or genetic information could 
have a negatively impact on a patient’s personal and professional life. Ethical concerns 
about secondary use of data most frequently revolve around potential harm to 
individual data subjects. Re-use of sensitive data personal data requires always very 
careful consideration. 
The principles of handling personal data are important in secondary use of 
health data. These have been embedded in the General Data Protection Regulation. It 
must be emphasized that all the principles apply regardless of whether there is a 
“primary” or “secondary” use of data. Purpose can be problematic if the secondary use 
was not anticipated and the subject did not give his or her informed consent when the 
data was collected. The application of the process and the standards will typically 
require specific consideration of individual systems and data check flows. A Data 
Privacy Impact Assessment (DIA) and the designation of a DPO will minimize the risk of 
breaches in personal health data.  
 
7.4 Incidental findings-subject’s information 
 
Incidental findings are a major ethical dilemma in medical research. Participants 
must be given an informed consent form and detailed information sheets that: state 
what procedures will be implemented in the event of unexpected or incidental findings 
(in particular, whether the participants have the right to know, or not to know, about 
any such findings)148. As genetic knowledge increases, it is now feasible to identify a 
variety of genetic findings for most participants unrelated to the primary focus of the 
study. In the context of genetic testing, the “right not to know” is the concept that any 
individual should be permitted to control whether they receive genetic information—
particularly information about the risk of future illness—and that their desire not to 
know certain kinds of information should be respected. The justifications for a right 
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not to know are grounded in respect for decisional autonomy and/or an interest in 
protecting individuals from receiving unwanted and potentially harmful information149.  
Conversely, there are many challenges in the consent process. Researchers will 
not know the likely findings for any specific participant or donor. Thus, the benefits 
and risks of receiving such data and other relevant information will need to be framed 
in general terms. Informed consent must, furthermore evaluate the effect on the 
patient’s family, because, for example genetics is linked to heredity and filiation and 
his or her right to autonomy in relation to incidental findings .In any case the decision 
of whether the incidental findings will be disclosed rests only with the involved data 
subject. 
 
7.5 Data Transfers  
 
The GDPR preserve requirements for data transfers outside the EU. Article 44 
of the General Data Protection Regulation sets out the general principles for allowing 
transfers to third countries, including any onward transfer, “Any transfer of personal 
data which are undergoing processing or are intended for processing after transfer to a 
third country or to an international organisation shall take place only if, subject to the 
other provisions of this Regulation, the conditions laid down in this Chapter are 
complied with by the controller and processor, including for onward transfers of 
personal data from the third country or an international organisation to another third 
country or to another international organisation”. 
The Data Protection Directive had a broad definition of territorial scope150, and 
the General Data Protection Regulation expands it even further. EU data protection 
law has a general position that the rights of EU data subjects should be protected 
regardless of where the data is processed. Such transfers occur, for example, when 
persons located in the US have access to data stored in the EU. When personal data 
collected in the EU is transferred to another country outside the protection of the 
Regulation, important restrictions apply. Moreover, special categories of data, such as 
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health data, there must further be a specific legal ground for processing. The 
Regulation provides for three requirements for a transfer of data outside EU: 
1. The Commission has enacted an adequacy decision about the adequate level of 
the legal framework of data privacy in a country, a territory or one or more 
specified sectors within that country according to Article 45 of the GDPR. 
2.  Data may be transferred if appropriate safeguards are available, on the 
condition that enforceable data subject rights and effective legal remedies for 
data subjects are available according to Article 46 of the new Regulation. 
3. Article 49 sets out derogations in the absence of the aforementioned adequacy 
decision or appropriate safeguards. That are the existence of an explicit 
informed consent from the data subject where he or she has been informed of 
the possible risk of transfer, the transfer is necessary due to a contract 
involving the data subject, an important reason of public interest or in 
connection to a legal claim, the transfer is necessary in order to protect the 
vital interests of the data subject or of other persons, where the data subject is 
physically or legally incapable of giving consent, the transfer is made from a 
register which according to Union or Member State law is intended to provide 
information to the public. Moreover, according to Article 49 “where a transfer 
could not be based on a provision in Article 45 or 46, including the provisions on 
binding corporate rules, and none of the derogations for a specific situation 
referred to in the first subparagraph of this paragraph is applicable, a transfer 
to a third country or an international organisation may take place only if the 
transfer is not repetitive, concerns only a limited number of data subjects, is 
necessary for the purposes of compelling legitimate interests pursued by the 
controller which are not overridden by the interests or rights and freedoms of 
the data subject, and the controller has assessed all the circumstances 
surrounding the data transfer and has on the basis of that assessment provided 
suitable safeguards with regard to the protection of personal data. The 
controller shall inform the supervisory authority of the transfer. The controller 
shall, in addition to providing the information referred to in Articles 13 and 14, 
inform the data subject of the transfer and on the compelling legitimate 
interests pursued”. 
  -65- 
The Safe Harbor Agreement (SHA)151 was a set of principles drafted in the year 
2000 and an example of adequacy decision under the Data Protection Directive that 
governed the transfer of user data from the European Union and Switzerland to the 
United States. It was ruled invalid by the European Court of Justice in October 2015. 
Safe Harbor included seven principles of notice, choice, onward transfer, security, 
access, integrity and enforcement. The agreement itself was annexed to an actual 
decision enacted by the Commission. US importers have to comply with these 
principles, to publicly certify their compliance with the US Department of Commerce 
and subject themselves to enforcement by the US Federal Trade Commission to the 
extent their certification materially misrepresented any aspect of their processing of 
personal data imported from Europe152. One of the most important data privacy cases 
arose from a complaint against Facebook brought to the Irish Data Protection 
Commissioner by an Austrian privacy advocate named Max Schrems. In the complaint, 
Mr. Schrems challenged the transfer of his data and the data of EU citizens to the 
United States by Facebook, which is incorporated in Ireland. The case was brought 
before the Court of Justice of the European Union and on October 6, 2015 CJEU 
invalidated the Safe Harbor arrangement, which governed data transfers between the 
EU and the US153. A new adequacy decision, after the CJEU invalidation, the EU-US 
Privacy Shield154, was enacted in July 2016 .The Privacy Principles of the EU-US Privacy 
Shield included thirteen Framework Principles similar to those in the Safe Harbor-
agreement. The agreement also includes Supplemental Principles.  
Transfer of data within medical research from the EU must comply with the 
requirements set out by the Regulation. The principles that are enshrined in Safe 
Harbor, the Schrems-case and EU-US Privacy Shield are important for medical 
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research, as they present a standard level of protection that EU data subjects must 
enjoy. 
 
Conclusions 
GDPR is a challenging Regulation. It brings additional protection of personal 
data but also raises issues that will need time to overcome in order to fully implement 
all the changes that it requires.  
 GDPR has directly affected data privacy and security standards while in 
addition indirectly drives all organisations that keep and process personal data to 
develop and improve their cyber security measures, in order to avoid any potential 
data breach. Furthermore, Data Protection Agencies from each Member State evaluate 
GDPR compliance consequently the Regulation standardized throughout EU the 
regulatory environment.  
In health and sensitive data in general, the GDPR provides to every patient the 
opportunity to gain more control over the personal data that is being collected and 
processed about them, as well as the purposes the data are used. One of the core 
components of the GDPR, the purpose and the location of any data that’s collected, 
ensures that healthcare providers will have a more detailed examination of their 
patients, which could direct to improved, and more correct diagnosis, as well as more 
targeted treatments.  
The recent incidents in data breaches are evident of the need for enhanced 
protection. Cambridge Analytica in March 2018 was reported to illegally sourced 
Facebook data and used them to influence a variety of political campaigns. The 
personal data of approximately 87 million Facebook users were acquired, without their 
knowledge and their consent155. In 2017 the WannaCry cyber attack156 affected 
multiple organisations including healthcare services like National Health Services 
hospitals in England and Scotland and was unprecedented in scale.157 
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On the other hand, departure from the rules of the GDPR in sensitive data 
processing, must take place only when the public interest undoubtedly prevails over a 
corresponding right in protecting and preserving individual privacy and autonomy. The 
rationale must be clearly and specifically demonstrated, and balanced against actual 
evidence of consequent benefits and risks. Especially in health data and clinical 
research the balance must be case-specific evaluated , and should be implemented by 
a body or institution that is familiar with, or structured to obtain and incorporate into 
its deliberative and decision-making process, multiple perspectives on the research 
context, associated privacy challenges158. Cross-border research involving human 
biological material that contains identifiable genetic information about a research 
participant requires harmonization with other non EU jurisdictions in order to be 
facilitated and provide reliable outcomes without the breach of the Regulation. Some 
of the requirements of GDPR are relatively easily addressed by putting in place data 
protection policies for all clinical research involving humans. Other prerequisites of the 
GDPR probably will increase the bureaucratic burden of sharing, at least on a large 
scale, human derived iPSC cells and data and will require additional administrative 
support such as the appointment of specialist Data Protection Officer and the 
constantly assessment and revision of a DIA. In biobanking data minimization and 
transfer of samples outside Europe also will be potentially the most challenging 
development159.A move toward digital tools for consent and engagement may offset 
some of the administrative burden of sustained interaction160. Concurrently, the 
retention of quality, safety, data protection, traceability and other GDPR conditions is 
likely to result in high running costs for Biobanks. To meet these costs cell banks may 
have to leverage the value of well-characterized iPSC to the pharmaceutical industry 
through longer term engagement between public and private sectors161. A possible 
failure to comply with the rules of GDPR may result not only in restraining research 
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development using iPSC but in hitting the public trust and support for this significant 
aspect of medical research. 
Moreover, harm due to the exclusion of health data usage, or data non-use, is a 
matter that needs attention. The large administrative process and the complicated 
requirements of GDPR on data access perhaps will result in non usage of health data. 
Also, it can be argued that, in some cases the pursuit of informed consent can 
disadvantage certain groups, particularly those who are hard to reach or are on the 
edges of society162.  
Reaching the most advantageous balance is challenging and unlikely to be 
stable over time. The balance must protect individual right in medical data protection 
in accordance with the promotion of innovation in clinical research.  
. 
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